JP6440625B2 - 精神分裂病を処置するための方法および組成物 - Google Patents
精神分裂病を処置するための方法および組成物 Download PDFInfo
- Publication number
- JP6440625B2 JP6440625B2 JP2015542047A JP2015542047A JP6440625B2 JP 6440625 B2 JP6440625 B2 JP 6440625B2 JP 2015542047 A JP2015542047 A JP 2015542047A JP 2015542047 A JP2015542047 A JP 2015542047A JP 6440625 B2 JP6440625 B2 JP 6440625B2
- Authority
- JP
- Japan
- Prior art keywords
- oxo
- pharmaceutically acceptable
- polymorph
- butanamide
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261726440P | 2012-11-14 | 2012-11-14 | |
| US61/726,440 | 2012-11-14 | ||
| PCT/US2013/070144 WO2014078568A1 (en) | 2012-11-14 | 2013-11-14 | Methods and compositions for treating schizophrenia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018024298A Division JP2018090609A (ja) | 2012-11-14 | 2018-02-14 | 精神分裂病を処置するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015537003A JP2015537003A (ja) | 2015-12-24 |
| JP2015537003A5 JP2015537003A5 (https=) | 2017-01-05 |
| JP6440625B2 true JP6440625B2 (ja) | 2018-12-19 |
Family
ID=50731694
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015542047A Active JP6440625B2 (ja) | 2012-11-14 | 2013-11-14 | 精神分裂病を処置するための方法および組成物 |
| JP2018024298A Withdrawn JP2018090609A (ja) | 2012-11-14 | 2018-02-14 | 精神分裂病を処置するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018024298A Withdrawn JP2018090609A (ja) | 2012-11-14 | 2018-02-14 | 精神分裂病を処置するための方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20140206667A1 (https=) |
| EP (2) | EP2919788A4 (https=) |
| JP (2) | JP6440625B2 (https=) |
| CA (1) | CA2891122C (https=) |
| HK (1) | HK1215170A1 (https=) |
| WO (1) | WO2014078568A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| WO2014144663A1 (en) * | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| AU2014228512A1 (en) | 2013-03-15 | 2015-10-01 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| KR20220049612A (ko) | 2014-01-21 | 2022-04-21 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
| HUE053734T2 (hu) | 2014-01-21 | 2021-07-28 | Janssen Pharmaceutica Nv | 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk |
| KR101634440B1 (ko) | 2014-08-21 | 2016-06-30 | 서울대학교산학협력단 | AMPA 수용체 GluA1의 인산화 억제제를 포함하는 정신질환의 예방 또는 치료용 약학조성물 |
| CA2986598C (en) | 2015-05-22 | 2023-09-26 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| WO2017195144A1 (en) * | 2016-05-12 | 2017-11-16 | Jubilant Generics Limited | Pharmaceutical compositions comprising brivaracetam |
| CN106109402A (zh) * | 2016-07-20 | 2016-11-16 | 南通雅本化学有限公司 | 一种左乙拉西坦注射液 |
| ES2769286T3 (es) | 2016-12-20 | 2020-06-25 | Lts Lohmann Therapie Systeme Ag | Sistema terapéutico transdérmico que contiene asenapina |
| WO2018115010A1 (en) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| US11253173B1 (en) * | 2017-05-30 | 2022-02-22 | Verily Life Sciences Llc | Digital characterization of movement to detect and monitor disorders |
| ES2881783T3 (es) | 2017-06-26 | 2021-11-30 | Lts Lohmann Therapie Systeme Ag | Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona |
| CN112533593A (zh) | 2018-06-20 | 2021-03-19 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| CA3101420A1 (en) | 2018-06-20 | 2019-12-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| CA3189302A1 (en) * | 2020-07-10 | 2022-01-13 | Agenebio, Inc. | Combinations of gabaa alpha 5 agonists and sv2a inhibitors and methods of using in the treatment of cognitive impairment |
Family Cites Families (731)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US759A (en) | 1838-05-30 | Reacting watek-wheels | ||
| US5516A (en) | 1848-04-18 | Combining lantebns and lamps | ||
| US1015498A (en) | 1911-03-01 | 1912-01-23 | Edward L Kraus | Folding-desk blackboard. |
| NL181407B (nl) | 1952-09-20 | Merck & Co Inc | Verbetering van een werkwijze ter bereiding van een farmaceutisch preparaat met antibacteriele werking, dat een combinatie van een verbinding van het 3-fluor-d-alaninetype en een cycloserineverbinding bevat. | |
| GB1309692A (en) | 1970-02-13 | 1973-03-14 | Ucb Sa | N-substituted lactams |
| GB1039113A (en) | 1964-08-06 | 1966-08-17 | Ucb Sa | New n-substituted lactams |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| JP2000319257A (ja) | 1969-01-06 | 2000-11-21 | Eisai Co Ltd | １−ベンジル−４−［（５，６−ジメトキシ−２−フルオロ−１−インダノン）−２−イル］メチルピペリジン |
| US3953603A (en) | 1973-11-05 | 1976-04-27 | Eli Lilly And Company | Hexahydro-dibenzo[b,d,]pyran-9-ones as psychotropic, particularly anti-depressant drugs |
| US4018895A (en) | 1974-01-10 | 1977-04-19 | Eli Lilly And Company | Aryloxyphenylpropylamines in treating depression |
| IT1045043B (it) | 1975-08-13 | 1980-04-21 | Isf Spa | Derivati pirrolidinici |
| NL7605526A (nl) | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
| IT1075280B (it) | 1977-02-11 | 1985-04-22 | Isf Spa | Procedimento per la preparazione di derivati pirrolidinici |
| BE864269A (fr) | 1977-03-03 | 1978-06-16 | Parke Davis & Co | Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire |
| JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| ATE27T1 (de) | 1978-05-08 | 1981-04-15 | Ucb Sa | Lactam-n-essigsaeuren und ihre amide, verfahren zu ihrer herstellung und heilmittel, die sie enthalten |
| US4654370A (en) | 1979-03-12 | 1987-03-31 | Abbott Laboratories | Glyceryl valproates |
| US4431649A (en) | 1979-07-30 | 1984-02-14 | Pfizer Inc. | Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents |
| US4337250A (en) | 1979-07-30 | 1982-06-29 | Pfizer Inc. | Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents |
| US4352807A (en) | 1979-07-30 | 1982-10-05 | Pfizer Inc. | Hexahydro-trans-pyridoindole neuroleptic agents |
| US4465683A (en) | 1979-09-14 | 1984-08-14 | Mead Johnson & Company | Anti-psychotic agents |
| US4254124A (en) | 1979-09-24 | 1981-03-03 | Mead Johnson & Company | Antidepressant agent |
| US4372960A (en) | 1980-12-12 | 1983-02-08 | Warner-Lambert Company | Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators |
| US4427679A (en) | 1981-01-16 | 1984-01-24 | Pfizer Inc. | Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents |
| FR2515179A1 (fr) | 1981-07-24 | 1983-04-29 | Hoffmann La Roche | Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique |
| US4415085A (en) | 1981-12-21 | 1983-11-15 | Eli Lilly And Company | Dry pharmaceutical system |
| PT77267B (en) | 1982-09-07 | 1986-03-21 | Lilly Co Eli | Improved process for preparing novel octahydrobenz <f> isoquinolines or compounds relating thereto |
| PT77268B (en) | 1982-09-07 | 1986-03-21 | Lilly Co Eli | Improved process for preparing novel bridged hexahydrobenz <f> isoquinolines or compounds relating thereto |
| US4476307A (en) | 1982-09-20 | 1984-10-09 | Pfizer Inc. | Heteroylidene indolone compounds |
| US4977178A (en) | 1982-09-20 | 1990-12-11 | Pfizer Inc. | Method of treating anxiety and depression with 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents |
| US4879391A (en) | 1982-09-20 | 1989-11-07 | Pfizer Inc. | 1-Phenyl-2(1H,3H)-indolone psychotherapeutic agents |
| US4495187A (en) | 1982-10-18 | 1985-01-22 | Pfizer Inc. | Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents |
| IL67623A (en) | 1983-01-05 | 1984-09-30 | Teva Pharma | 1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it |
| IL72381A (en) | 1983-07-20 | 1988-03-31 | Sanofi Sa | Pharmaceutical composition based on valproic acid |
| US4547501A (en) | 1983-09-02 | 1985-10-15 | Pfizer Inc. | Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents |
| US4599339A (en) | 1983-09-26 | 1986-07-08 | Eli Lilly And Company | Use of pyrimido[4,5-g]quinolines in treating parkinsonism |
| US4558070A (en) | 1983-10-26 | 1985-12-10 | Abbott Laboratories | Acid salts of valproic acid |
| US4605655A (en) | 1984-03-06 | 1986-08-12 | Bristol-Myers Company | Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives |
| GB8412357D0 (en) | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| GB8412358D0 (en) | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| US4668687A (en) | 1984-07-23 | 1987-05-26 | Bristol-Myers Company | Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones |
| US4593037A (en) | 1984-07-26 | 1986-06-03 | Pfizer Inc. | 1,3-disubstituted piperidine compounds as neuroleptic agents |
| US4619930A (en) | 1985-01-16 | 1986-10-28 | Bristol-Myers Company | Antipsychotic cyclic imide derivatives of 2-(4-butylpiperazin-1-yl)pyridines, compositions and use |
| US4913906B1 (en) | 1985-02-28 | 2000-06-06 | Yissum Res Dev Co | Controlled release dosage form of valproic acid |
| IL74497A (en) | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| US4656173A (en) | 1985-04-24 | 1987-04-07 | Bristol-Myers Company | Antipsychotic benzisothiazole S-oxide compound |
| US4677104A (en) | 1985-05-06 | 1987-06-30 | Bristol-Myers Company | Antipsychotic fused-ring pyridinylpiperazine derivatives |
| JPS6222785A (ja) | 1985-07-23 | 1987-01-30 | Sanwa Kagaku Kenkyusho:Kk | 新規な２−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤 |
| US4663318A (en) | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| IT1190133B (it) | 1986-06-19 | 1988-02-10 | Chiesi Farma Spa | Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| US4757073A (en) | 1986-09-30 | 1988-07-12 | Bristol-Myers Company | Antipsychotic cyclic imide derivatives of 2-(4-butylipiperazin-1-yl) pyridines, compositions and use |
| US4816456A (en) | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
| DD263531A5 (de) | 1986-10-21 | 1989-01-04 | ������@���Kk�� | Verfahren zur herstellung von verbrueckten bicyclischen imidverbindungen |
| EP0363415B1 (en) | 1987-05-04 | 2008-10-15 | Davis, Bonnie | Compounds for the treatment of alzheimer's disease |
| MX174210B (es) | 1987-02-17 | 1994-04-28 | Pfizer | Procedimiento para la preparacion de compuestos arilpiperazinil-alquilenfenil-p-heterociclicos |
| MX173362B (es) | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| US4771053A (en) | 1987-03-02 | 1988-09-13 | Bristol-Myers Company | Method for alleviation of primary depressive disorders |
| HU201906B (en) | 1987-03-04 | 1991-01-28 | Sandoz Ag | Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them |
| PH25124A (en) | 1987-03-17 | 1991-02-19 | Hoechst Roussel Pharma | Substituted 9-amino-tetrahydro acridines and related compounds |
| DE3709230A1 (de) | 1987-03-20 | 1988-10-06 | Desitin Arzneimittel Gmbh | Neues calciumsalz der valproinsaeure |
| IT1225462B (it) | 1987-04-03 | 1990-11-14 | Mediolanum Farmaceutici Srl | Sali organici di derivati della fisostigmina |
| US4784998A (en) | 1987-04-06 | 1988-11-15 | Bristol-Myers Company | 1,3,4-oxadiazole pyschotropic compounds |
| US5002955A (en) | 1987-04-23 | 1991-03-26 | Hoechst-Roussel Pharmaceuticals Inc. | Fused heteroalkylene quinolinamines and use as cholinergic agents |
| US5187165A (en) | 1987-05-15 | 1993-02-16 | Hoechst-Roussel Pharmaceuticals Inc. | Memory enhancing and analgesic 1,2,3a,8,8a-hexahydro-3a,8(and 1,3a,8)-di(and tri)methylpyrrolo[2,3-b]indoles |
| US4931447A (en) | 1987-06-15 | 1990-06-05 | Eli Lilly And Company | Cycloalkylamides of (8β)-1-alkyl-6-(substituted) ergolines |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| JPS6422883A (en) | 1987-07-17 | 1989-01-25 | Sanwa Kagaku Kenkyusho Co | 1-pyrrolidine acetamide derivative, its salt, production thereof and prophylactic and remedial agent for cereral dysfunction containing said derivative and salt as active ingredient |
| ES2026198T3 (es) | 1987-07-22 | 1992-04-16 | Farvalsa Ag | Compuesto a base de acido valproico solido, estable a la humedad y metodo para su preparacion. |
| US5364863A (en) | 1987-09-08 | 1994-11-15 | Eli Lilly And Company | Specific 5-HT3 antagonists |
| ZA886585B (en) | 1987-09-08 | 1990-05-30 | Lilly Co Eli | Specific 5-ht,antagonists |
| US4880930A (en) | 1987-11-30 | 1989-11-14 | New James S | Psychotropic acyclic amide derivatives |
| US4891375A (en) | 1988-01-13 | 1990-01-02 | Pfizer Inc. | Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds |
| US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US4883795A (en) | 1988-01-22 | 1989-11-28 | Pfizer Inc. | Piperazinyl-heterocyclic compounds |
| US5001130A (en) | 1988-02-18 | 1991-03-19 | Bristol-Myers Company | Psychotropic heterobicycloalkylpiperazine derivatives |
| US5238959A (en) | 1988-04-08 | 1993-08-24 | Eli Lilly And Company | 3-phenyloxy-3-phenyl propanamines |
| US5242911A (en) | 1988-06-17 | 1993-09-07 | Pfizer Inc. | Bridged bicyclic imides as anxiolytics and antidepressants |
| FI911285A7 (fi) | 1988-09-16 | 1991-03-15 | Pfizer | Antipsykoottisia bisyklisiä 4-/4-(3-bentsisotiatsolyyli)-1-piperatsiny yli/butyylisiltaimidejä |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| US5254556A (en) | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
| US5158952A (en) | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
| CA2000786C (en) | 1988-11-07 | 1999-01-26 | Janssen Pharmaceutica, Naamloze Vennootschap | 3-piperidinyl-1,2-benzisoxazoles |
| MX18467A (es) | 1988-11-23 | 1993-07-01 | Pfizer | Agentes terapeuticos de quinuclidinas |
| WO1990006303A1 (en) | 1988-12-02 | 1990-06-14 | Pfizer Inc. | Arylpiperidine derivatives |
| US4950658A (en) | 1988-12-06 | 1990-08-21 | Board Of Trustees Of Southern Illinois Univ. | Method of medical treatment of Alzheimer's disease |
| IL93051A0 (en) | 1989-01-17 | 1990-11-05 | Hoffmann La Roche | ((5-oxo-2-pyrrolidinyl)methyl)cyclohexaneacetamides,their preparation and pharmaceutical compositions containing them |
| MX19185A (es) | 1989-01-20 | 1993-12-01 | Pfizer | Procedimiento para preparar 3-(1,2,5,6-tretrahidropiridil)-pirrolopiridinas. |
| FR2643556B1 (fr) | 1989-02-27 | 1993-03-05 | Sanofi Sa | Composition pharmaceutique a liberation prolongee d'acide valproique |
| US4981870A (en) | 1989-03-07 | 1991-01-01 | Pfizer Inc. | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
| US5238945A (en) | 1989-04-11 | 1993-08-24 | H. Lundbeck A/S | Method of treating psychoses |
| GB8908085D0 (en) | 1989-04-11 | 1989-05-24 | Lundbeck & Co As H | New therapeutic use |
| US4963689A (en) | 1989-05-19 | 1990-10-16 | Pfizer Inc. | Heterocyclicguanidines as 5HT3 antagonists |
| US4914207A (en) | 1989-05-09 | 1990-04-03 | Pfizer Inc. | Arylthiazolylimidazoles |
| ES2076253T3 (es) | 1989-05-19 | 1995-11-01 | Hoechst Roussel Pharma | N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos. |
| US5364866A (en) | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| US5693668A (en) | 1989-06-22 | 1997-12-02 | Merrell Pharmaceuticals Inc. | Acetylcholinesterase inhibitors |
| EP0403713A1 (en) | 1989-06-22 | 1990-12-27 | Merrell Dow Pharmaceuticals Inc. | Novel acetylcholinesterase inhibitors |
| US5350747A (en) | 1989-07-07 | 1994-09-27 | Pfizer Inc | Heteroaryl piperazine antipsychotic agents |
| WO1991000863A1 (en) | 1989-07-07 | 1991-01-24 | Pfizer Inc. | Heteroaryl piperazine antipsychotic agents |
| IT1231477B (it) | 1989-07-12 | 1991-12-07 | Sigma Tau Ind Farmaceuti | (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
| US4956368A (en) | 1989-07-24 | 1990-09-11 | Bristol-Myers Company | Metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione |
| US5006525A (en) | 1989-07-24 | 1991-04-09 | Eli Lilly And Company | Dopamine agonists method |
| US4999430A (en) | 1989-07-31 | 1991-03-12 | Warner-Lambert Company | Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine |
| DE3927049A1 (de) | 1989-08-16 | 1991-02-21 | Sandoz Ag | Halogenalkyl-phenyl-ketone und deren hydrate, ihre herstellung und verwendung |
| US5387590A (en) | 1989-08-30 | 1995-02-07 | Pfizer Inc. | Benzazabicyclic carbamates as novel cholinesterase inhibitors |
| US4914102A (en) | 1989-09-28 | 1990-04-03 | Hoechst Roussel Pharmaceuticals, Inc. | N-aminocarbamates related to physostigmine, pharmacentical compositions and use |
| US5011841B1 (en) | 1989-11-14 | 1994-09-06 | Pfizer | Treatment of depression |
| UA41251C2 (uk) | 1990-01-04 | 2001-09-17 | Пфайзер, Інк. | Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі |
| US5232929A (en) | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
| NZ237241A (en) | 1990-03-02 | 1993-11-25 | Pharmetrix Corp | Method for increasing the storage stability of physostigmine |
| US5043341A (en) | 1990-04-11 | 1991-08-27 | Eli Lilly And Company | N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| DE69105131T2 (de) | 1990-06-01 | 1995-03-23 | Pfizer | 3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen. |
| JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
| JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| US5399565A (en) | 1990-07-17 | 1995-03-21 | Eli Lilly And Company | Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof |
| US5102891A (en) | 1990-07-23 | 1992-04-07 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates |
| HUT62584A (en) | 1990-07-23 | 1993-05-28 | Pfizer | Process for producing quinuclidine derivatives |
| US5264442A (en) | 1990-08-13 | 1993-11-23 | Hoechst-Roussel Pharmaceuticals Incorporated | Carbamoyl-1-(pyridinylalkyl)-1H-indoles, indolines and related analogs |
| TW200462B (https=) | 1990-09-27 | 1993-02-21 | Hoechst Roussel Pharma | |
| DE69109125T2 (de) | 1990-09-28 | 1995-09-28 | Pfizer | Ringverknüpfte analoge von stickstoffenthaltenden nichtaromatischen heterocyclen. |
| PL170330B1 (pl) | 1990-10-15 | 1996-11-29 | Pfizer | Sposób wytwarzania nowych pochodnych indolu PL PL PL PL PL PL |
| US5578612A (en) | 1990-10-15 | 1996-11-26 | Pfizer Inc. | Indole derivatives |
| US5559129A (en) | 1990-10-15 | 1996-09-24 | Pfizer Inc | Indole derivatives |
| US5190951A (en) | 1990-10-19 | 1993-03-02 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| US5147881A (en) | 1990-11-14 | 1992-09-15 | Pfizer Inc | 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents |
| JP2965675B2 (ja) | 1990-11-21 | 1999-10-18 | エーザイ株式会社 | （―）―１―ベンジル―４―〔（５，６―ジメトキシ―１―インダノン）―２―イル〕メチルピペリジンの製造方法 |
| TW197435B (https=) | 1990-11-22 | 1993-01-01 | Takeda Pharm Industry Co Ltd | |
| JPH04327532A (ja) | 1991-01-31 | 1992-11-17 | Bristol Myers Squibb Co | 活動過剰を伴う注意力欠乏疾患の治療に使用する医薬製剤 |
| US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US5157034A (en) | 1991-02-27 | 1992-10-20 | Pfizer Inc. | Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines |
| WO1992015585A1 (en) | 1991-03-01 | 1992-09-17 | Pfizer Inc. | 1-azabicyclo[3.2.2]nonan-3-amine derivatives |
| US5334720A (en) | 1991-03-07 | 1994-08-02 | Fisons Corporation | Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties |
| US5750542A (en) | 1993-09-28 | 1998-05-12 | Pfizer | Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors |
| WO1992017475A1 (en) | 1991-03-28 | 1992-10-15 | Pfizer Inc. | Heterocyclic-cyclic amine derivatives |
| US5627178A (en) | 1991-04-23 | 1997-05-06 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US5817656A (en) | 1991-04-23 | 1998-10-06 | Eli Lilly And Company | Mental disorders |
| US5817655A (en) | 1991-04-23 | 1998-10-06 | Eli Lilly And Company | Methods of treatment using a thieno-benzodiazepine |
| US5104880A (en) | 1991-05-01 | 1992-04-14 | Mayo Foundation For Medical Education And Research | Huperzine a analogs as acetylcholinesterase inhibitors |
| CA2067614C (en) | 1991-05-02 | 2002-07-30 | Eiichi Otomo | Agent for improving dementia |
| US5716965A (en) | 1991-05-22 | 1998-02-10 | Pfizer Inc. | Substituted 3-aminoquinuclidines |
| FR2677019B1 (fr) | 1991-05-27 | 1994-11-25 | Pf Medicament | Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique. |
| AU657552B2 (en) | 1991-05-31 | 1995-03-16 | Pfizer Inc. | Quinuclidine as substance P antagonists |
| US5106856A (en) | 1991-06-07 | 1992-04-21 | Hoechst-Roussel Pharmaceuticals Inc. | [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds |
| DE69213451T2 (de) | 1991-06-20 | 1997-01-09 | Pfizer Inc., New York | Fluoralkoxybenzylaminoderivate stickstoffhaltiger heterocyclen |
| TW202432B (https=) | 1991-06-21 | 1993-03-21 | Pfizer | |
| FR2679555B1 (fr) | 1991-07-25 | 1993-11-19 | Fabre Medicament Pierre | Nouveaux derives de l'uree, leur preparation et leur application en therapeutique. |
| CZ281628B6 (cs) | 1991-07-29 | 1996-11-13 | Warner-Lambert Company | Deriváty chinazolinu a farmaceutické přípravky na jejich bázi |
| IT1251166B (it) | 1991-08-09 | 1995-05-04 | Chiesi Farma Spa | Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono |
| US5161533A (en) | 1991-09-19 | 1992-11-10 | Xomed-Treace Inc. | Break-apart needle electrode system for monitoring facial EMG |
| US5246947A (en) | 1991-09-23 | 1993-09-21 | Hoechst-Roussel Pharmaceuticals Incorporated | Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression |
| US5565453A (en) | 1991-09-25 | 1996-10-15 | Pfizer Inc. | Neuroleptic 2-substituted perhydro-1-h-pyrido[1,2-a]pyrazines |
| US5527808A (en) | 1991-09-26 | 1996-06-18 | Pfizer Inc. | Fused tricyclic nitrogen containing heterocycles |
| US5231093A (en) | 1991-10-01 | 1993-07-27 | Hoechst-Roussel Pharmaceuticals Incorporated | Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs |
| TW263504B (https=) | 1991-10-03 | 1995-11-21 | Pfizer | |
| EP0537993A1 (en) | 1991-10-17 | 1993-04-21 | Eli Lilly And Company | Nicotinic activity of a series of arecolones and isoarecolones |
| US5710168A (en) | 1991-10-23 | 1998-01-20 | Pfizer Inc. | 2-piperidino-1-alkanol derivatives as neuroprotective agents |
| CA2123403C (en) | 1991-11-12 | 2002-02-05 | Brian T. O'neill | Acyclic ethylenediamine derivatives as substance p receptor antagonists |
| BR9206810A (pt) | 1991-11-25 | 1995-10-31 | Pfizer | Derivados de indol |
| US5137894A (en) | 1991-12-05 | 1992-08-11 | New James S | 4-(4-Piperidinyl-thieno[3,2-c]pyridine derivatives of n-alkylglutarimides |
| ES2042384B1 (es) | 1991-12-26 | 1994-06-01 | Boehringer Ingelheim Espana | Procedimiento para obtener derivados bis-piridinicos. |
| EP0619814A1 (en) | 1991-12-31 | 1994-10-19 | Fujisawa Pharmaceutical Co., Ltd. | Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity |
| CA2129732A1 (en) | 1992-02-25 | 1993-09-02 | Alain Martin | Cytoprotective compositions containing pyruvate and antioxidants |
| TW288010B (https=) | 1992-03-05 | 1996-10-11 | Pfizer | |
| US5569662A (en) | 1992-03-23 | 1996-10-29 | Pfizer Inc. | Quinuclidine derivatives as substance P antagonists |
| SK280193B6 (sk) | 1992-04-07 | 1999-09-10 | Pfizer Inc. | Indolové deriváty predstavujúce 5-ht1 agonisty, fa |
| US6380233B1 (en) | 1992-04-07 | 2002-04-30 | Pfizer Inc | Indole derivatives as 5-HT1 agonists |
| US5498626A (en) | 1992-04-10 | 1996-03-12 | Pfizer Inc. | Acylaminoindole derivatives as 5-ht1 agonists |
| US5439930A (en) | 1992-04-14 | 1995-08-08 | Russian-American Institute For New Drug Development | Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects |
| US5256664A (en) | 1992-04-28 | 1993-10-26 | Bristol-Myers Squibb Company | Antidepressant 3-halophenylpiperazinylpropyl derivatives of substituted triazolones and triazoldiones |
| US20050256162A1 (en) | 1992-05-05 | 2005-11-17 | Pfizer Inc | Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles |
| JP2757234B2 (ja) | 1992-05-18 | 1998-05-25 | ファイザー インク． | Ｐ物質拮抗薬としての架橋アザ二環式誘導体 |
| IT1254996B (it) | 1992-06-25 | 1995-10-11 | Mediolanum Farmaceutici Srl | Esteri amminoalchilcarbammici dell'eserolina atti all'impiego come anticolinesterasici e relativo procedimento di preparazione |
| EP0654029A1 (en) | 1992-08-04 | 1995-05-24 | Pfizer Inc. | 3-benzylamino-2-phenyl-piperidine derivatives as substance p receptor antagonists |
| WO1994004496A1 (en) | 1992-08-19 | 1994-03-03 | Pfizer Inc. | Substituted benzylamino nitrogen containing non-aromatic heterocycles |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| US5440023A (en) | 1992-09-18 | 1995-08-08 | Beckman Instruments, Inc. | Method for making valproic acid derivatives |
| US5604241A (en) | 1992-10-21 | 1997-02-18 | Pfizer Inc. | Substituted benzylaminoquinuclidines as substance P antagonists |
| US5837711A (en) | 1992-10-28 | 1998-11-17 | Pfizer Inc. | Substituted quinuclidines as substance P antagonists |
| TW251284B (https=) | 1992-11-02 | 1995-07-11 | Pfizer | |
| US5498610A (en) | 1992-11-06 | 1996-03-12 | Pfizer Inc. | Neuroprotective indolone and related derivatives |
| CA2149242C (en) | 1992-11-12 | 1998-08-04 | Fumitaka Ito | Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders |
| ATE194340T1 (de) | 1992-12-10 | 2000-07-15 | Pfizer | Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten |
| US6369074B1 (en) | 1992-12-10 | 2002-04-09 | Pfizer Inc. | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists |
| US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
| ATE177101T1 (de) | 1992-12-17 | 1999-03-15 | Pfizer | Pyrrolopyrimidine als crf antagonisten |
| TW370529B (en) | 1992-12-17 | 1999-09-21 | Pfizer | Pyrazolopyrimidines |
| EP0611769A1 (en) | 1993-02-16 | 1994-08-24 | Merrell Dow Pharmaceuticals Inc. | Silylated acetylcholinesterase inhibitors |
| AU4982293A (en) | 1993-03-02 | 1994-09-26 | Fujisawa Pharmaceutical Co., Ltd. | Novel heterocyclic compound |
| ATE166650T1 (de) | 1993-03-04 | 1998-06-15 | Pfizer | Spiroazacyclischderivate als substanz p antagonisten |
| ATE201403T1 (de) | 1993-03-16 | 2001-06-15 | Pfizer | Naphtalinderivate |
| IL109646A0 (en) | 1993-05-19 | 1994-08-26 | Pfizer | Heteroatom substituted alkyl benzylamino-quinuclidines |
| EP0627400A1 (en) | 1993-06-04 | 1994-12-07 | Merrell Dow Pharmaceuticals Inc. | Aromatic acetylcholinesterase inhibitors |
| SE9302080D0 (sv) | 1993-06-16 | 1993-06-16 | Ab Astra | New compounds |
| EP0708771B1 (en) | 1993-07-15 | 1998-10-07 | Pfizer Inc. | Benzyloxyquinuclidines as substance p antagonists |
| DK0716649T3 (da) | 1993-08-31 | 1999-02-08 | Pfizer | 5-Arylindolderivater |
| US6083943A (en) | 1993-09-17 | 2000-07-04 | Pfizer Inc | Substituted azaheterocyclecarboxylic acid |
| EP1209157A1 (en) | 1993-09-17 | 2002-05-29 | Pfizer Inc. | Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds |
| GB9319732D0 (en) | 1993-09-24 | 1993-11-10 | Ucb Sa | Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety |
| US5468733A (en) | 1993-09-30 | 1995-11-21 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| CZ282567B6 (cs) | 1993-12-29 | 1997-08-13 | Pfizer Inc. | Diazabicyklické sloučeniny a farmaceutické prostředky na jejich bázi |
| JP4099224B2 (ja) | 1994-03-02 | 2008-06-11 | ナームローゼ・フエンノートチヤツプ・オルガノン | 舌下又はバッカル医薬組成物 |
| WO1995029909A1 (en) | 1994-04-29 | 1995-11-09 | Pfizer Inc. | Novel acyclic and cyclic amides as neurotransmitter release enhancers |
| WO1995034563A1 (en) | 1994-06-16 | 1995-12-21 | Pfizer Inc. | Pyrazolo and pyrrolopyridines |
| US5744476A (en) | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
| CA2193388C (en) | 1994-06-29 | 2005-07-26 | Bertrand L. Chenard | Aryl and heteroaryl alkoxynaphthalene derivatives |
| EP0773942A1 (en) | 1994-07-26 | 1997-05-21 | Pfizer Inc. | 4-indole derivatives as serotonin agonists and antagonists |
| KR100224961B1 (ko) | 1994-08-18 | 1999-10-15 | 디. 제이. 우드 | 신경보호성 3-(피페리디닐-1)-크로만-4,7-디올 및 1-(4-하이드로페닐)-2-(피페리디닐-1)-알칸올 유도체 |
| US5597826A (en) | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
| US5627200A (en) | 1994-09-26 | 1997-05-06 | Pfizer Inc | β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia |
| WO1996010570A1 (en) | 1994-09-30 | 1996-04-11 | Pfizer Inc. | NEUROLEPTIC 2,7-DISUBSTITUTED PERHYDRO-1H-PYRIDO[1,2-a]PYRAZINES |
| US5516759A (en) | 1994-12-08 | 1996-05-14 | Tap Holdings Inc. | LHRH antagonists having lactam groups at the N-terminus |
| US5658590A (en) | 1995-01-11 | 1997-08-19 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
| US5741789A (en) | 1995-01-17 | 1998-04-21 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| US5576321A (en) | 1995-01-17 | 1996-11-19 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| WO1996024353A1 (en) | 1995-02-10 | 1996-08-15 | Eli Lilly And Company | Methods of treating or preventing psychiatric disorders |
| CR5278A (es) | 1995-03-24 | 1996-07-04 | Lilly Co Eli | Formulacion oral de 2-metil-tieno-benzodiacepina |
| EG23659A (en) | 1995-03-24 | 2007-03-26 | Lilly Co Eli | Process and crystal forms of methyl-thieno-benzodiazepine |
| AU5317996A (en) | 1995-04-18 | 1996-11-07 | Eli Lilly And Company | Method for using ergoline compounds to effect physiological and pathological functions at the 5-ht7 receptor |
| US5889010A (en) | 1995-05-18 | 1999-03-30 | Pfizer Inc. | Benzimidazole derivatives having dopaminergic activity |
| US20010023248A1 (en) | 1995-05-25 | 2001-09-20 | Howard Harry R. | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists |
| US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
| US6180647B1 (en) | 1995-07-07 | 2001-01-30 | Pfizer Inc. | Substituted benzolactam compounds as substance P antagonists |
| US5696168A (en) | 1995-07-24 | 1997-12-09 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
| NZ313076A (en) | 1995-07-24 | 1999-11-29 | Lilly Co Eli | Medicament containing duloxetine for treating hyperactivity and attention deficiency disorders |
| TW340842B (en) | 1995-08-24 | 1998-09-21 | Pfizer | Substituted benzylaminopiperidine compounds |
| IL115113A (en) | 1995-08-31 | 2002-11-10 | Israel State | 3-carbamoyloxy pyridinium derivatives and pharmaceutical compositions containing them |
| ES2100129B1 (es) | 1995-10-11 | 1998-02-16 | Medichem Sa | Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion. |
| WO1997019059A1 (en) | 1995-11-17 | 1997-05-29 | Sibia Neurosciences, Inc. | Novel substituted aryl compounds useful as modulators of acetylcholine receptors |
| US5783584A (en) | 1995-12-11 | 1998-07-21 | Mayo Foundation For Medical Education And Research | THA analogs useful as cholinesterase inhibitors |
| EP0780375B1 (en) | 1995-12-21 | 2002-09-11 | Pfizer Inc. | 3-((5-substituted benzyl)amino)-2-phenylpiperidines as substance p antagonists |
| PL327600A1 (en) | 1995-12-22 | 1998-12-21 | Lilly Co Eli | Method of treating depressions |
| US5625897A (en) | 1996-01-11 | 1997-05-06 | Park; Kelly R. | Upper torso garment |
| AU1582197A (en) | 1996-01-22 | 1997-08-11 | Eli Lilly And Company | Combinatorial process for preparing substituted indane libraries |
| GB9606736D0 (en) | 1996-02-19 | 1996-06-05 | Shire International Licensing | Therapeutic method |
| WO1997033577A1 (en) | 1996-03-11 | 1997-09-18 | Eli Lilly And Company | Method for treating bipolar disorder |
| WO1997035584A1 (en) | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Method for treating pain |
| US6107300A (en) | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
| US6326368B1 (en) | 1996-03-27 | 2001-12-04 | Dupont Pharmaceuticals Company | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof |
| PT891332E (pt) | 1996-03-29 | 2004-07-30 | Pfizer | Derivados de 6-fenilpiridil-2-amina |
| NZ325914A (en) | 1996-03-29 | 1999-09-29 | Pfizer | Benzyl(idene)-lactam derivatives and salts thereof, their preparation and their use as selective (ant)agonists of 5-ht1a and/or 5-ht1d receptors and thus are effective as psychotherapeutic agents |
| CA2252039C (en) | 1996-04-12 | 2002-12-24 | Hoechst Marion Roussel, Inc. | Isatin derivatives as acetylcholinesterase inhibitors and analgesics |
| TW491847B (en) | 1996-05-07 | 2002-06-21 | Pfizer | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one |
| US6110918A (en) | 1996-05-07 | 2000-08-29 | Pfizer Inc | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist |
| TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| US5948437A (en) | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
| EP1380298A3 (en) | 1996-05-23 | 2004-04-07 | Bristol-Myers Squibb Pharma Company | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders, anorexia, inflammation |
| ZA973884B (en) | 1996-05-23 | 1998-11-06 | Du Pont Merck Pharma | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders |
| DE69708968T2 (de) | 1996-05-28 | 2002-04-25 | Pfizer Inc., New York | Arylacrylamidderivate als 5HT1 Agoniste oder Antagoniste |
| AU1153097A (en) | 1996-06-07 | 1998-01-05 | Eisai Co. Ltd. | Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production |
| TW513409B (en) | 1996-06-07 | 2002-12-11 | Eisai Co Ltd | Polymorphs of donepezil hydrochloride |
| US6329396B1 (en) | 1996-06-10 | 2001-12-11 | Pfizer Inc. | Substituted benzylaminopiperidine compounds |
| US5912256A (en) | 1996-06-20 | 1999-06-15 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| CA2180703A1 (en) | 1996-07-08 | 1998-01-09 | Paul Marie Victor Gilis | Fast-dissolving galanthamine hydrobromide tablet |
| US7094782B1 (en) | 1996-07-24 | 2006-08-22 | Bristol-Myers Squibb Company | Azolo triazines and pyrimidines |
| HU228962B1 (en) | 1996-07-24 | 2013-07-29 | Bristol Myers Squibb Pharma Co | Azolo triazines, pharmaceutical compositions containing them and use of the compounds |
| US6191131B1 (en) | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| US6117890A (en) | 1996-08-01 | 2000-09-12 | Eli Lilly And Company | Method for treating bipolar disorder |
| US6043258A (en) | 1996-08-01 | 2000-03-28 | Eli Lilly And Company | Method for treating disruptive behavior disorders with xanomeline |
| PT821955E (pt) | 1996-08-01 | 2002-07-31 | Lilly Co Eli | Uso de 3-(4-hexiloxi-1,2,5-tiadiazol-3-il)-1,2,5,6-tetrahidro-1-metilpiridina (xanomelina) para o tratamento da doenca bipolar |
| MX9706196A (es) | 1996-08-14 | 1998-02-28 | Pfizer | Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p. |
| AU4078997A (en) | 1996-08-22 | 1998-03-06 | New York University | Cholinesterase inhibitors for treatment of parkinson's disease |
| ZA977967B (en) | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| CZ299247B6 (cs) | 1996-09-23 | 2008-05-28 | Eli Lilly And Company | Olanzapin dihydrát D |
| UA56185C2 (uk) | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування |
| US6423708B1 (en) | 1996-09-30 | 2002-07-23 | Pfizer Inc | Aralkyl and aralkylidene heterocyclic lactams and imides |
| IT1285801B1 (it) | 1996-10-10 | 1998-06-24 | Sigma Tau Ind Farmaceuti | Procedimento migliorato per la preparazione dell'acido valproico |
| WO1998018798A1 (en) | 1996-10-30 | 1998-05-07 | Pfizer Inc. | Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy |
| WO1998030243A1 (en) | 1997-01-08 | 1998-07-16 | Warner-Lambert Company | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
| PT1270565E (pt) | 1997-01-29 | 2004-09-30 | Pfizer | Furano-2-sulfonamida 4-substituida e sua utilizacao na preparacao de derivados de sulfonilureia |
| US6020335A (en) | 1997-02-06 | 2000-02-01 | Pfizer Inc | (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents |
| EP0971713B1 (en) | 1997-03-03 | 2003-05-28 | Eisai Co., Ltd. | Use of cholinesterase inhibitors to treat disorders of attention |
| GB2323788B (en) | 1997-04-02 | 1999-02-17 | Bristol Myers Squibb Co | Venting valve for ostomy bag |
| NZ337698A (en) | 1997-04-04 | 2001-07-27 | Pfizer Prod Inc | Nicotinamide derivatives for selective inhibition of phosphodiesterase type 4 (PDE4) and the production of tumour necrosis factor (TNF) useful for the treatment of respiratory, rheumatoid and allergic diseases |
| ZA982877B (en) | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
| WO1998046225A1 (en) | 1997-04-11 | 1998-10-22 | Eli Lilly And Company | Method for treating schizophrenia |
| US6284771B1 (en) | 1997-04-11 | 2001-09-04 | Eli Lilly And Company | Method for treating schizophrenia |
| US5910319A (en) | 1997-05-29 | 1999-06-08 | Eli Lilly And Company | Fluoxetine enteric pellets and methods for their preparation and use |
| US6627755B1 (en) | 1997-06-09 | 2003-09-30 | Pfizer Inc | Quinazolin-4-one AMPA antagonists |
| US6060479A (en) | 1997-06-09 | 2000-05-09 | Pfizer Inc | Quinazoline-4-one AMPA antagonists |
| ES2245015T3 (es) | 1997-06-09 | 2005-12-16 | Pfizer Products Inc. | Quinazolin-4-onas como antagonistas de ampa. |
| JP2001510797A (ja) | 1997-07-22 | 2001-08-07 | イーライ・リリー・アンド・カンパニー | 医薬化合物 |
| GB9716879D0 (en) | 1997-08-08 | 1997-10-15 | Shire Int Licensing Bv | Treatment of attention deficit disorders |
| AU8742198A (en) | 1997-08-15 | 1999-03-08 | Shire International Licensing B.V. | Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity |
| US6479523B1 (en) | 1997-08-26 | 2002-11-12 | Emory University | Pharmacologic drug combination in vagal-induced asystole |
| IL125951A (en) | 1997-09-05 | 2003-09-17 | Pfizer Prod Inc | A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal |
| US6323208B1 (en) | 1997-09-05 | 2001-11-27 | Pfizer Inc | Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones |
| AU9214498A (en) | 1997-09-23 | 1999-04-12 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
| UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| US6245911B1 (en) | 1997-12-05 | 2001-06-12 | Eisai Co., Ltd. | Donepezil polycrystals and process for producing the same |
| CA2304967C (en) | 1997-12-16 | 2005-06-14 | Warner-Lambert Company | 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
| IL127497A (en) | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
| EP1049699B1 (en) | 1998-01-28 | 2004-04-21 | Bristol-Myers Squibb Pharma Company | Pyrazolotriazines as crf antagonists |
| US6131106A (en) | 1998-01-30 | 2000-10-10 | Sun Microsystems Inc | System and method for floating-point computation for numbers in delimited floating point representation |
| AU2495399A (en) | 1998-02-06 | 1999-08-23 | Eli Lilly And Company | Desert hedgehog related nucleic acids and proteins |
| GB9805561D0 (en) | 1998-03-16 | 1998-05-13 | Merck Sharp & Dohme | A combination of therapeutic agents |
| PA8469101A1 (es) | 1998-04-09 | 2000-09-29 | Pfizer Prod Inc | Ligandos azabiciclicos de receptores 5ht1 |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| ATE228119T1 (de) | 1998-04-15 | 2002-12-15 | Pfizer Prod Inc | Heterocyclische carboxamide |
| ES2226284T3 (es) | 1998-04-16 | 2005-03-16 | Pfizer Products Inc. | N-acil y n-aroil-aralquilamidas. |
| JP2002515435A (ja) | 1998-05-21 | 2002-05-28 | イーライ・リリー・アンド・カンパニー | 鬱病処置のための組合せ治療 |
| BR9911049A (pt) | 1998-05-22 | 2001-02-06 | Lilly Co Eli | Terapia combinada para tratamento de depressão resistente |
| US6960577B2 (en) | 1998-05-22 | 2005-11-01 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
| GT199900060A (es) | 1998-05-22 | 2000-10-14 | Polimorfos de un monoclorhidrato de pirazina cristalino y sus composiciones farmacèuticas. | |
| IL139591A0 (en) | 1998-05-29 | 2002-02-10 | Lilly Co Eli | Combination therapy for treatment of bipolar disorders |
| US6150366A (en) | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
| US6436914B1 (en) | 1998-06-30 | 2002-08-20 | Bristol-Myers Squibb Company | 2-hydroxy-3—(4-hydroxy-3-sulfonamidophenyl)—propylamines useful as beta 3 adrenergic agonists |
| US6312717B1 (en) | 1998-07-07 | 2001-11-06 | Bristol-Myers Squibb Company | Method for treatment of anxiety and depression |
| US6262081B1 (en) | 1998-07-10 | 2001-07-17 | Dupont Pharmaceuticals Company | Composition for and method of treating neurological disorders |
| US6218383B1 (en) | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
| JP2002522541A (ja) | 1998-08-11 | 2002-07-23 | ファイザー・プロダクツ・インク | ホスホジエステラーゼ４阻害剤としての置換１，８−ナフチリジン−４（１ｈ）−オン |
| IL125809A (en) | 1998-08-17 | 2005-08-31 | Finetech Lab Ltd | Process and intermediates for production of donepezil and related compounds |
| IT1304904B1 (it) | 1998-09-11 | 2001-04-05 | Eisai Co Ltd | Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche |
| HN1999000146A (es) | 1998-09-21 | 2000-11-11 | Pfizer Prod Inc | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas. |
| PL348107A1 (en) | 1998-10-16 | 2002-05-06 | Janssen Pharmaceutica Nv | Therapy for improving cognition |
| US5994352A (en) | 1998-11-13 | 1999-11-30 | Pfizer Inc. | 5-arylindole derivatives |
| WO2000030446A1 (en) | 1998-11-23 | 2000-06-02 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
| US6627771B1 (en) | 1998-11-25 | 2003-09-30 | Pfizer Inc | Gamma amino butyric and acid analogs |
| JP2002531502A (ja) | 1998-12-11 | 2002-09-24 | デイビス、ボニー | 視床下部−下垂体−生殖腺軸変調に於けるアセチルコリンエステラーゼ阻害剤の使用 |
| UA62015C2 (en) | 1998-12-28 | 2003-12-15 | Pfizer Prod Inc | Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants) |
| US6271380B1 (en) | 1998-12-30 | 2001-08-07 | Dupont Pharmaceuticals Company | 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands |
| WO2000041684A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | A pharmaceutical combination for the treatment of depression |
| ATE289586T1 (de) | 1999-03-01 | 2005-03-15 | Pfizer Prod Inc | Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor |
| EA004229B1 (ru) | 1999-03-01 | 2004-02-26 | Пфайзер Продактс Инк. | Оксаминовые кислоты и их производные в качестве лигандов тиреоидных рецепторов |
| US6277866B1 (en) | 1999-03-03 | 2001-08-21 | Eisai Co., Ltd. | 1-benzyl-4[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine |
| DK1086706T3 (da) | 1999-03-31 | 2004-03-08 | Eisai Co Ltd | Stabiliserede sammensætninger indeholdende nootropiske lægemidler |
| EP1050303A3 (en) | 1999-04-27 | 2003-01-15 | Pfizer Products Inc. | Methods and compositions for treating age-related behavioral disorders in companion animals |
| WO2000071107A2 (en) | 1999-05-21 | 2000-11-30 | Pfizer Products Inc. | New pharmaceutical combinations for nos inhibitors |
| WO2000074784A1 (en) | 1999-06-09 | 2000-12-14 | Eli Lilly And Company | Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist |
| MXPA01012969A (es) | 1999-06-15 | 2003-10-14 | Bristol Myers Squibb Pharma Co | Gamma-carbolinas fusionadas de heterociclo sustituido. |
| US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| US6524616B1 (en) | 1999-06-25 | 2003-02-25 | Wake Forest University Health Services | Compositions and methods for treating or preventing neurodegeneration and cognitive decline and dysfunction associated with alzheimer's disease, aging, other dementia related disorders and estrogen deficiency related conditions |
| US6432989B1 (en) | 1999-08-27 | 2002-08-13 | Pfizer Inc | Use of CRF antagonists to treat circadian rhythm disorders |
| ES2284519T3 (es) | 1999-09-01 | 2007-11-16 | EISAI R&D MANAGEMENT CO., LTD. | Derivados de piperidina 4-sustituida. |
| JP4242048B2 (ja) | 1999-09-01 | 2009-03-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ４−置換ピペリジン誘導体 |
| HK1043590A1 (zh) | 1999-09-22 | 2002-09-20 | Schering Corporation | 毒蕈碱性拮抗物 |
| EP1088819B1 (en) | 1999-09-30 | 2005-06-15 | Pfizer Products Inc. | 6-azauracil derivatives as thyroid receptor ligands |
| CA2324813A1 (en) | 1999-11-10 | 2001-05-10 | Susan Beth Sobolov-Jaynes | Combination treatment for depression and anxiety |
| US6620802B1 (en) | 1999-11-23 | 2003-09-16 | Corcept Therapeutics, Inc. | Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist |
| CA2475026A1 (en) * | 1999-12-01 | 2001-06-07 | Ucb, S.A. | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders |
| EP1244666A1 (en) | 1999-12-17 | 2002-10-02 | Bristol-Myers Squibb Pharma Company | Imidazopyrimidinyl and imidazopyridinyl derivatives |
| AU3789901A (en) | 1999-12-17 | 2001-06-25 | Bristol-Myers Squibb Company | Antipsychotic heterocycle compounds |
| ATE266660T1 (de) | 1999-12-20 | 2004-05-15 | Lilly Co Eli | Piperidin-derivate und ihre verwendung als serotonin rezeptor antagonisten |
| AU1930901A (en) | 1999-12-20 | 2001-07-03 | Eli Lilly And Company | Azabicyclo(3.2.1)octane derivatives |
| US6835733B2 (en) | 1999-12-20 | 2004-12-28 | Eli Lilly And Company | Tropane linked benzofuran derivatives |
| AU2049601A (en) | 1999-12-20 | 2001-07-03 | Eli Lilly And Company | Benzofuran derivatives |
| ES2259619T3 (es) | 1999-12-20 | 2006-10-16 | Eli Lilly And Company | Derivados de indol para el tratamiento de depresion y ansiedad. |
| ES2225031T3 (es) | 1999-12-29 | 2005-03-16 | Pfizer Products Inc. | Compuestos de 3-((2-piperazinil-fenil)metil)-1-(4-(trifluorometil)fenil)-2-pirrolidinona opticamente activos como antagonistas selectivos del receptor de 5-ht1d. |
| EP1127882A1 (en) | 2000-01-25 | 2001-08-29 | Pfizer Products Inc. | Tetrazole compounds as thyroid receptor ligands |
| CZ20022771A3 (cs) | 2000-02-17 | 2003-09-17 | Bristol-Myers Squibb Company | Ligandy thyreoidního receptoru odvozené od anilinu |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| EP1311272B1 (en) | 2000-03-03 | 2006-11-22 | Eisai Co., Ltd. | Novel methods using cholinesterase inhibitors |
| WO2001066096A2 (en) | 2000-03-06 | 2001-09-13 | Immune Network Ltd. | Compositions for prevention and treatment of dementia |
| US6911476B2 (en) | 2000-03-13 | 2005-06-28 | Eli Lilly And Company | Sulfonamide derivatives |
| WO2001072692A1 (en) | 2000-03-31 | 2001-10-04 | Pfizer Products Inc. | Malonamic acids and derivatives thereof as thyroid receptor ligands |
| US6664291B2 (en) | 2000-03-31 | 2003-12-16 | Pfizer, Inc. | Malonamic acids and derivatives thereof as thyroid receptor ligands |
| GB0007884D0 (en) | 2000-03-31 | 2000-05-17 | Pfizer Ltd | Diphenyl ether compounds useful in therapy |
| ATE350378T1 (de) | 2000-04-08 | 2007-01-15 | Boehringer Ingelheim Pharma | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| PL358623A1 (en) | 2000-04-10 | 2004-08-09 | Pfizer Products Inc. | Benzoamide piperidine compounds as substance p antagonists |
| JP4150519B2 (ja) | 2000-04-13 | 2008-09-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | １−ベンジルピリジニウム塩を含有してなるアセチルコリンエステラーゼ阻害剤 |
| US6620830B2 (en) | 2000-04-21 | 2003-09-16 | Pfizer, Inc. | Thyroid receptor ligands |
| US20010036949A1 (en) | 2000-05-09 | 2001-11-01 | Coe Jotham Wadsworth | Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
| US6630469B2 (en) | 2000-05-09 | 2003-10-07 | Bristol-Myers Squibb Company | 5-HT7 receptor antagonists |
| US20040229911A1 (en) | 2000-05-17 | 2004-11-18 | Pfizer Inc | New pharmaceutical combinations for NOS inhibitors |
| AU2001261022A1 (en) | 2000-05-24 | 2001-12-03 | Eli Lilly And Company | Combination therapy for treatment of depression comprising an antidepressant and an ampa receptor potentiator |
| US6893858B2 (en) | 2000-05-26 | 2005-05-17 | Bristol-Myers Squibb Company | Human kcnq5 potassium channel, methods and compositions thereof |
| DK1468686T3 (da) | 2000-06-02 | 2007-03-12 | Pfizer Prod Inc | S-methyl-dihydro-ziprasidon til behandling af psykiatriske lidelser |
| US6395784B1 (en) | 2000-06-07 | 2002-05-28 | Bristol-Myers Squibb Company | Benzamide ligands for the thyroid receptor |
| DOP2001000189A (es) | 2000-06-30 | 2002-03-30 | Pfizer Prod Inc | Benzofenonas y sulfonas como inhibidores de la captación de glicina |
| EP1316203A2 (en) | 2000-06-30 | 2003-06-04 | Eli Lilly And Company | Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist |
| US6630476B2 (en) | 2000-07-07 | 2003-10-07 | Bristol-Myers Squibb Pharma Company | Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists |
| EP1177792A3 (en) | 2000-07-27 | 2002-10-23 | Pfizer Products Inc. | Dopamine D4 Ligands for the treatment of novelty-seeking disorders |
| US6756385B2 (en) | 2000-07-31 | 2004-06-29 | Pfizer Inc. | Imidazole derivatives |
| US20020016334A1 (en) | 2000-07-31 | 2002-02-07 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) |
| US20020049211A1 (en) | 2000-09-06 | 2002-04-25 | Sobolov-Jaynes Susan Beth | Combination treatment for depression and anxiety |
| WO2002019998A2 (en) | 2000-09-08 | 2002-03-14 | Eli Lilly And Company | A method of treating weight gain associated with atypical antipsychotic use |
| HUP0303038A2 (hu) | 2000-09-21 | 2003-12-29 | Bristol-Myers Squibb Co. | Szubsztituált azolszármazékok mint kortikotropin releasing faktor inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
| EP1192952A3 (en) | 2000-09-28 | 2003-03-26 | Pfizer Products Inc. | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist |
| IL145584A0 (en) | 2000-10-02 | 2002-06-30 | Pfizer Prod Inc | Nmda nr2b antagonists for treatment |
| US20020151591A1 (en) | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
| US20020103198A1 (en) | 2000-12-04 | 2002-08-01 | Fliri Anton F.J | Acylamino cyclopropane derivatives |
| CA2364211A1 (en) | 2000-12-05 | 2002-06-05 | Phillip Branch Chappell | Combination treatment for depression, anxiety and psychosis |
| UA73619C2 (en) | 2000-12-13 | 2005-08-15 | Pfizer Prod Inc | Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment |
| ES2260335T3 (es) | 2000-12-20 | 2006-11-01 | Bristol-Myers Squibb Pharma Company | Derivados de pirazinoquinoxalina como agonistas y antagonistas de serotonina. |
| US6849619B2 (en) | 2000-12-20 | 2005-02-01 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
| PL366233A1 (en) | 2000-12-20 | 2005-01-24 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
| EE200300303A (et) | 2000-12-20 | 2003-12-15 | Bristol-Myers Squibb Company | Asendatud pürrolokinoliinid ja püridokinoliinid kui serotoniini agonistid ja antagonistid |
| KR100823668B1 (ko) | 2000-12-28 | 2008-04-21 | 해밀턴 파마슈티컬스 인코포레이티드 | 신경성 통증 치료 및 예방약 |
| US20020086871A1 (en) | 2000-12-29 | 2002-07-04 | O'neill Brian Thomas | Pharmaceutical composition for the treatment of CNS and other disorders |
| US6436938B1 (en) | 2001-01-22 | 2002-08-20 | Pfizer Inc. | Combination treatment for depression |
| KR20040034594A (ko) | 2001-01-26 | 2004-04-28 | 브리스톨-마이어스스퀴브컴파니 | 코르티코트로핀 방출 인자 억제제로서의 이미다졸릴 유도체 |
| US20020107244A1 (en) | 2001-02-02 | 2002-08-08 | Howard Harry R. | Combination treatment for depression |
| US6610326B2 (en) | 2001-02-16 | 2003-08-26 | Andrx Corporation | Divalproex sodium tablets |
| US20040116505A1 (en) | 2001-02-23 | 2004-06-17 | Gregory Krauss | Treatment of tics, tremors and related disorders |
| US20020123490A1 (en) | 2001-03-01 | 2002-09-05 | Pfizer Inc. | Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis |
| WO2002072101A1 (en) | 2001-03-13 | 2002-09-19 | Bristol-Myers Squibb Pharma Company | A corticotropin releasing factor receptor ligand, its enantiomer and pharmaceutically acceptable salts |
| BR0208357A (pt) | 2001-03-13 | 2004-06-29 | Bristol Myers Squibb Pharma Co | Composto, composição farmacêutica, método de antagonização de um receptor de fator de liberação de corticotropina (crf), método de tratamento de disfunção, método de triagem de ligantes, método de detecção de receptores de crf, método de inibição da ligação de crf, artigo industrializado e usos do composto |
| EP1372620A2 (en) | 2001-03-15 | 2004-01-02 | Saegis Pharmaceuticals | Methods for restoring cognitive function following systemic stress |
| DE60222396T2 (de) | 2001-03-29 | 2008-05-15 | Eli Lilly And Co., Indianapolis | N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste |
| JP2004531506A (ja) | 2001-03-29 | 2004-10-14 | ブリストル−マイヤーズ スクイブ カンパニー | 選択的なセロトニン再取り込みインヒビターとしてのシクロプロピルインドール誘導体 |
| SK12822003A3 (sk) | 2001-04-19 | 2004-04-06 | Warner - Lambert Company Llc | Fúzne bicyklické alebo tricyklické aminokyseliny |
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| US20030018047A1 (en) | 2001-04-20 | 2003-01-23 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| IL149106A0 (en) | 2001-04-20 | 2002-11-10 | Pfizer Prod Inc | Therapeutic use of selective pde10 inhibitors |
| EP1666886A3 (en) | 2001-04-20 | 2006-06-21 | Pfizer Products Inc. | Method of identifying selective PDE10 inhibitor compounds |
| AU2756602A (en) | 2001-04-25 | 2002-10-31 | Pfizer Products Inc. | Methods and kits for treating depression or preventing deterioration of cognitive function |
| MY129350A (en) | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
| US20020165217A1 (en) | 2001-05-01 | 2002-11-07 | Pfizer Inc. | Combination treatment for anxiety and depression |
| EP1256578B1 (en) | 2001-05-11 | 2006-01-11 | Pfizer Products Inc. | Thiazole derivatives and their use as cdk inhibitors |
| CA2446980A1 (en) | 2001-05-14 | 2002-11-21 | Argyrios G. Arvanitis | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands |
| WO2002094787A1 (en) | 2001-05-23 | 2002-11-28 | Ucb, S.A. | 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders |
| EP1260221A3 (en) | 2001-05-23 | 2002-12-18 | Pfizer Products Inc. | Combination treatment for depression and anxiety |
| US6566550B2 (en) | 2001-06-21 | 2003-05-20 | Pfizer Inc | Substituted aromatic ethers as inhibitors of glycine transport |
| US20030008892A1 (en) | 2001-07-09 | 2003-01-09 | Pfizer Inc. | Pharmaceutical composition and method of modulating cholinergic function in a mammal |
| AU2002354575A1 (en) | 2001-07-12 | 2003-01-29 | Bristol-Myers Squibb Pharma Company | Tetrahydropurinones as corticotropin releasing factor |
| WO2003006015A1 (en) | 2001-07-13 | 2003-01-23 | Bristol-Myers Squibb Pharma Company | Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands |
| WO2003010161A1 (en) | 2001-07-24 | 2003-02-06 | Bristol-Myers Squibb Company | S-6-hydroxy-buspirone |
| WO2003009851A1 (en) | 2001-07-24 | 2003-02-06 | Bristol-Myers Squibb Company | R-6-hydroxy-buspirone |
| US8354438B2 (en) | 2001-08-08 | 2013-01-15 | Michael Chez | Neurological functions |
| ES2248493T3 (es) | 2001-08-16 | 2006-03-16 | Pfizer Products Inc. | Difluorometilen-eteres aromaticos y su uso como inhibidores del transportador de glicina tipo 1. |
| CA2457982C (en) | 2001-08-22 | 2009-11-03 | Daiichi Pharmaceutical Co., Ltd. | Use of nefiracetam for treating neurodegeneration |
| CA2459146A1 (en) | 2001-08-30 | 2003-03-13 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors |
| WO2003022820A1 (en) | 2001-09-06 | 2003-03-20 | Bristol-Myers Squibb Pharma Company. | Heteroaromatic substituted cyclopropane as corticotropin releasing hormone |
| DE60208132T2 (de) | 2001-09-26 | 2006-07-20 | Pfizer Products Inc., Groton | Indolcaroboxylsäure als Thyroidrezeptor-Liganden |
| US20040235957A1 (en) | 2001-10-12 | 2004-11-25 | David Bleakman | Use of sulfonamide derivatives as pharmaceuticals compounds |
| CN1604776A (zh) | 2001-10-16 | 2005-04-06 | 记忆药物公司 | 作为用于治疗神经病综合症的pde－4抑制剂的4－(4－烷氧基－3－羟基苯基)－2－吡咯烷酮衍生物 |
| KR20010113584A (ko) | 2001-11-08 | 2001-12-28 | (주)시스튜디오 | 컴퓨터에 의한 만화 애니메이션 구현방법 및 만화애니메이션 실행데이터를 기록한 컴퓨터로 읽을 수 있는기록매체 |
| US6673811B1 (en) | 2001-11-19 | 2004-01-06 | Neurogen Corporation | 1H-pyrrolo [3,2-b] pyridine-3-carboxylic acid amines as GABAA receptor ligands |
| US20030119831A1 (en) | 2001-11-20 | 2003-06-26 | Hartz Richard A. | 3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands |
| US6992087B2 (en) | 2001-11-21 | 2006-01-31 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
| MXPA02010430A (es) | 2001-11-27 | 2003-06-02 | Warner Lambert Co | Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas. |
| BR0213581A (pt) | 2001-12-11 | 2004-08-24 | Lilly Co Eli | Uso de um inibidor de recaptação de norepinefrina seletivo |
| US6495700B1 (en) | 2002-01-09 | 2002-12-17 | Axonyx, Inc. | Process for producing phenserine and its analog |
| US20050009927A1 (en) | 2002-01-23 | 2005-01-13 | Pfizer Inc | Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors |
| US20050014848A1 (en) | 2002-01-23 | 2005-01-20 | Pfizer Inc. | Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors |
| JP2005532268A (ja) | 2002-02-22 | 2005-10-27 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 置換されたピリミジノンおよびピリミジンチオン |
| US20040167200A1 (en) | 2002-03-25 | 2004-08-26 | Pfizer Inc. | Pharmaceutical composition and method of modulating cholinergic function in a mammal |
| GB0207104D0 (en) | 2002-03-26 | 2002-05-08 | Pfizer Ltd | Stable hydrate of a muscarinic receptor antagonist |
| US6759552B2 (en) | 2002-03-28 | 2004-07-06 | Council Of Scientific And Industrial Research | Compound as cholinesterase inhibitor and its isolation from fungus sporotrichum species |
| AU2003217936A1 (en) | 2002-03-28 | 2003-10-13 | Eli Lilly And Company | Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders |
| WO2003082820A1 (en) | 2002-03-29 | 2003-10-09 | Eisai Co., Ltd. | (1-indanone)-(1,2,3,6-tetrahydropyridine) derivative |
| WO2003084610A1 (en) | 2002-04-03 | 2003-10-16 | Eli Lilly And Company | Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist |
| CN1649845A (zh) | 2002-04-26 | 2005-08-03 | 先灵公司 | 蝇蕈碱拮抗剂 |
| US6713490B2 (en) | 2002-04-26 | 2004-03-30 | Pfizer, Inc. | 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists |
| WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| WO2003101458A1 (en) | 2002-05-31 | 2003-12-11 | H. Lundbeck A/S | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
| US6710040B1 (en) | 2002-06-04 | 2004-03-23 | Pfizer Inc. | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors |
| US20040001895A1 (en) | 2002-06-17 | 2004-01-01 | Pfizer Inc. | Combination treatment for depression and anxiety |
| US20030235631A1 (en) | 2002-06-17 | 2003-12-25 | Pfizer Inc. | Combination treatment for depression and anxiety |
| US20040006135A1 (en) | 2002-06-19 | 2004-01-08 | Pfizer Inc. | Combination treatment for depression and anxiety |
| US20040116506A1 (en) | 2002-06-20 | 2004-06-17 | Krusz John Claude | Use of levetiracetam for treating or preventing acute headaches |
| US6875771B2 (en) | 2002-07-26 | 2005-04-05 | Bristol-Myers Squibb Company | Pyridopyrimidine derivatives as 5-HT6 antagonists |
| AU2003264915A1 (en) | 2002-08-05 | 2004-02-25 | Eli Lilly And Company | Piperazine substituted aryl benzodiazepines |
| US7557137B2 (en) | 2002-08-05 | 2009-07-07 | Bristol-Myers Squibb Company | Gamma-lactams as beta-secretase inhibitors |
| US7053122B2 (en) | 2002-08-09 | 2006-05-30 | Pfizer Inc | Therapeutic use of aryl amino acid derivatives |
| GB0219154D0 (en) | 2002-08-16 | 2002-09-25 | Pfizer Ltd | Diaryl compounds |
| GB0219153D0 (en) | 2002-08-16 | 2002-09-25 | Pfizer Ltd | Substituted glycine derivatives for use as medicaments |
| CA2495864C (en) | 2002-08-20 | 2011-09-27 | Bristol-Myers Squibb Company | Aripiprazole complex formulation and method |
| WO2004024729A1 (en) | 2002-09-10 | 2004-03-25 | Pfizer Products Inc. | Diazabicyclic compounds useful in the treatment of cns and other disorders |
| TW200418838A (en) | 2002-09-18 | 2004-10-01 | Bristol Myers Squibb Co | Compounds for the treatment of premature ejaculation |
| WO2004026236A2 (en) | 2002-09-18 | 2004-04-01 | Bristol-Myers Squibb Company | Cyclopentyl indole derivatives |
| US7635709B2 (en) | 2002-09-26 | 2009-12-22 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction |
| US7067658B2 (en) | 2002-09-30 | 2006-06-27 | Bristol-Myers Squibb Company | Pyridino and pyrimidino pyrazinones |
| GB0223494D0 (en) | 2002-10-09 | 2002-11-13 | Neuropharma Sa | Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease |
| KR100755625B1 (ko) | 2002-10-24 | 2007-09-04 | 화이자 프로덕츠 인크. | 신경이완 활성을 갖는 5-(2-(4-(1,2벤즈이소티아졸-3-일)-1-피페라지닐)에틸)-6-클로로-1,3-디히드로-2ｈ-인돌-2-온의 아실 유도체 |
| KR100777904B1 (ko) | 2002-10-24 | 2007-11-28 | 메르츠 파마 게엠베하 운트 코. 카가아 | 1-아미노시클로헥산 유도체 및 아세틸콜린에스테라제 저해제를 포함하는 약학적 제품 및 이를 이용한 복합 치료 |
| GB0225379D0 (en) | 2002-10-31 | 2002-12-11 | Pfizer Ltd | Therapeutic proline derivatives |
| EP1565437A1 (en) | 2002-11-18 | 2005-08-24 | Pfizer Products Inc. | Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides |
| AU2003294442A1 (en) | 2002-11-22 | 2004-06-18 | Bristol-Myers Squibb Company | 3-heterocyclic benzylamide derivatives as potassium channel openers |
| AU2003295782A1 (en) | 2002-11-22 | 2004-06-18 | Bristol-Myers Squibb Company | Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers |
| EP1565190A4 (en) | 2002-11-22 | 2006-04-26 | Bristol Myers Squibb Co | ARYLCYCLOPROPYLCARBOXYLIC ACID AMIDE AS A KALIUM CHANNEL OPENER |
| US20040191803A1 (en) | 2002-11-22 | 2004-09-30 | Michela Gallagher | Target for therapy of cognitive impairment |
| US7087609B2 (en) | 2002-11-22 | 2006-08-08 | Bristol-Myers Squibb Company | 3-(pyridinyl-piperazin-1-yl)-phenylethyl amides as potassium channel openers |
| EP1581510A4 (en) | 2002-11-22 | 2006-08-30 | Bristol Myers Squibb Co | 1-ARYL-2-HYDROXYETHYLAMIDEALS CALIUM CHANNEL OPENER |
| US7090985B2 (en) | 2002-12-03 | 2006-08-15 | Ucb, S.A. | Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
| JP2006516390A (ja) | 2002-12-03 | 2006-07-06 | ユ セ ベ ソシエテ アノニム | 発作、神経系疾患、内分泌障害及びホルモン疾患の治療用薬剤の同定方法 |
| CA2509142A1 (en) | 2002-12-11 | 2004-06-24 | Pharmacia & Upjohn Company Llc | Combination for the treatment of adhd |
| KR20050085535A (ko) | 2002-12-11 | 2005-08-29 | 파마시아 앤드 업존 캄파니 엘엘씨 | 알파 7 니코틴성 아세틸콜린 수용체 아고니스트와 다른화합물의 조합물을 사용한 질환의 치료 방법 |
| MXPA05008137A (es) | 2003-01-31 | 2005-09-30 | Pfizer Prod Inc | Antagonistas y agonistas de 5ht7. |
| MXPA05009435A (es) | 2003-03-06 | 2005-11-23 | Celgene Corp | Metodos de uso y composiciones que contienen medicamentos inhibidores selectivos de citocina para el tratamiento y manejo de alteraciones del sistema nervioso central. |
| JP3910627B2 (ja) | 2003-03-12 | 2007-04-25 | ファイザー・プロダクツ・インク | ピリジルオキシメチルおよびベンゾイソオキサゾールのアザビシクロ環の誘導体 |
| ITMI20030573A1 (it) | 2003-03-24 | 2004-09-25 | Nikem Research Srl | Composti ad azione nootropica, loro preparazione, |
| US20040191334A1 (en) | 2003-03-24 | 2004-09-30 | Pang-Chui Shaw | Use of transhinone derivates as cholinesterase inhibitors in treating related diseases |
| BRPI0407926A (pt) | 2003-03-27 | 2006-02-21 | Pfizer Prod Inc | 4-amino[1,2,4]triazol[4,3-a]quinoxalinas substituìdas |
| TW200508197A (en) | 2003-03-31 | 2005-03-01 | Ucb Sa | Indolone-acetamide derivatives, processes for preparing them and their uses |
| US7041671B2 (en) | 2003-04-02 | 2006-05-09 | Pfizer Inc | Pyrrolo[1,2-b]pyridazine compounds and their uses |
| US7034023B2 (en) | 2003-04-04 | 2006-04-25 | Pfizer Inc | Pyrrolo[1,2-B]pyridazine compounds and their uses |
| US7056920B2 (en) | 2003-04-04 | 2006-06-06 | Pfizer Inc | Pyrrolo[1,2-B]pyridazine compounds and their uses |
| US7056930B2 (en) | 2003-04-14 | 2006-06-06 | Pfizer Inc. | 2-Azabicyclo[3.3.1]nonane derivatives |
| US20040204453A1 (en) | 2003-04-14 | 2004-10-14 | Pfizer Inc | 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors |
| BRPI0409307A (pt) | 2003-04-14 | 2006-04-25 | Pfizer Prod Inc | derivados de 3-azabiciclo[3.2.1]octano |
| US7030145B2 (en) | 2003-04-18 | 2006-04-18 | Bristol-Myers Squibb Company | Pyridinyl derivatives for the treatment of depression |
| US7112585B2 (en) | 2003-04-18 | 2006-09-26 | Bristol-Myers Squibb Company | Pyrimidine derivatives as corticotropin releasing factor inhibitors |
| MXPA05011387A (es) | 2003-04-23 | 2005-12-01 | Pharmacia & Upjohn Co Llc | Pirimidinonas y pirimidinotionas sustituidas. |
| GB0309440D0 (en) | 2003-04-25 | 2003-06-04 | Lilly Co Eli | Quinolone derivatives |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| WO2004099213A2 (en) | 2003-05-07 | 2004-11-18 | Pharmacia & Upjohn Company Llc | Pyrrolo (1,2-b) pyridazine compounds and their use as crf-1 receptor antagonists |
| EP1625115A1 (en) | 2003-05-09 | 2006-02-15 | Pharmacia & Upjohn Company LLC | Substituted pyrimidine derivatives |
| US20050038036A1 (en) | 2003-05-16 | 2005-02-17 | Pfizer Inc | Treatment of bipolar disorders and associated symptoms |
| EP1626722A1 (en) | 2003-05-16 | 2006-02-22 | Pfizer Products Inc. | Method for enhancing cognition using ziprasidone |
| WO2004100992A2 (en) | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines |
| MXPA05012391A (es) | 2003-05-16 | 2006-02-02 | Pfizer Prod Inc | Tratamiento de trastornos psicoticos y depresivos. |
| CN102166359A (zh) | 2003-05-23 | 2011-08-31 | 大塚制药株式会社 | 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂 |
| US7101881B2 (en) | 2003-06-11 | 2006-09-05 | Pfizer Inc | Tetrahydroquinolines |
| EP1638932A1 (en) | 2003-06-18 | 2006-03-29 | Pfizer Products Inc. | Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams |
| CA2525245C (en) | 2003-06-27 | 2010-10-19 | Pfizer Products Inc. | Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors |
| MXPA05014201A (es) | 2003-06-27 | 2006-02-24 | Pfizer Prod Inc | Pirazolo [3,4-b] piridin-6-onas como inhibidores de la gsk-3. |
| US20050070577A1 (en) | 2003-07-03 | 2005-03-31 | Pfizer Inc. | Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist |
| WO2005013961A1 (en) | 2003-07-17 | 2005-02-17 | Eli Lilly And Company | Combination therapy for treatment of cognitive disorders or psychoses |
| TW200510324A (en) | 2003-08-11 | 2005-03-16 | Lilly Co Eli | 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist |
| WO2005019168A2 (en) | 2003-08-20 | 2005-03-03 | Pfizer Products Inc. | Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors |
| US20060270656A1 (en) | 2003-09-09 | 2006-11-30 | Eli Lilly And Company | Substituted piperazines of azepines, oxazepines and thiazepines |
| EP1667686A1 (en) | 2003-09-09 | 2006-06-14 | Pfizer Products Inc. | Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors |
| GB0322140D0 (en) | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| US7244843B2 (en) | 2003-10-07 | 2007-07-17 | Bristol-Myers Squibb Company | Modulators of serotonin receptors |
| CA2541458C (en) | 2003-10-08 | 2011-09-20 | Eli Lilly And Company | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors |
| MXPA06003748A (es) | 2003-10-08 | 2006-06-14 | Pfizer | Compuestos de lactama condensada. |
| US20050080100A1 (en) | 2003-10-09 | 2005-04-14 | Pfizer Inc | Pyridylamino compounds and methods of use thereof |
| RU2006112576A (ru) | 2003-10-16 | 2006-08-27 | Пфайзер Продактс Инк. (Us) | Получение производных 3-азабицикло [3.1.0] гексана |
| JP2007508336A (ja) | 2003-10-16 | 2007-04-05 | ニューロサーチ、アクティーゼルスカブ | モノアミン神経伝達物質再取り込みインヒビター及びアセチルコリンエステラーゼインヒビターを含む医薬組成物 |
| US7795307B2 (en) | 2003-10-21 | 2010-09-14 | Colucid Pharmaceuticals, Inc. | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents |
| WO2005053701A1 (en) | 2003-11-26 | 2005-06-16 | Pfizer Products Inc. | Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides |
| ATE473967T1 (de) | 2003-11-26 | 2010-07-15 | Pfizer Prod Inc | Aminopyrazolderivate als gsk-3-inhibitoren |
| WO2005051488A1 (en) | 2003-11-26 | 2005-06-09 | Pfizer Products Inc. | Combination of dopamine agonists and monoamine reuptake inhibitors |
| EA010031B1 (ru) | 2003-12-02 | 2008-06-30 | Юсб, С.А. | Производные имидазола, способы их получения и применения |
| EP1729754B1 (en) | 2003-12-12 | 2008-07-02 | Eli Lilly And Company | Selective norepinephrine reuptake inhibitors for the treatment of hot flashes |
| MXPA06006812A (es) | 2003-12-15 | 2006-08-23 | Pfizer Prod Inc | Lactamas e imidas aralquilo y aralqulideno heterociclicas. |
| US20050227980A1 (en) | 2003-12-15 | 2005-10-13 | Pfizer Inc. | Aralkyl and aralkylidene heterocyclic lactam and imides |
| AP2006003633A0 (en) | 2003-12-19 | 2006-06-30 | Pfizer | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-BETA-hydroxysteroid dehydrogenase type 1 (11-BETA-HSD-1) for the treatment of diabetes and obesity |
| WO2005063296A2 (en) | 2003-12-23 | 2005-07-14 | Pfizer Products Inc. | Therapeutic combination for cognition enhancement and psychotic disorders |
| TW200522944A (en) | 2003-12-23 | 2005-07-16 | Lilly Co Eli | CB1 modulator compounds |
| US20050171095A1 (en) | 2004-01-06 | 2005-08-04 | Pfizer Inc | Combination of CRF antagonists and 5-HT1B receptor antagonists |
| US7642361B2 (en) | 2004-01-09 | 2010-01-05 | Eli Lilly And Company | Thiophene and furan compounds |
| US20050222123A1 (en) | 2004-01-27 | 2005-10-06 | North Shore-Long Island Jewish Research Institute | Cholinesterase inhibitors for treating inflammation |
| WO2005082372A1 (en) | 2004-01-29 | 2005-09-09 | Pfizer Products Inc. | COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS |
| JP2007519705A (ja) | 2004-01-29 | 2007-07-19 | ファイザー・プロダクツ・インク | Ｃｎｓ障害を治療するための非定型抗精神病薬とアミノメチルピリジルオキシメチル／ベンゾイソオキサゾールアザビシクロ誘導体の組合せ |
| WO2005074535A2 (en) | 2004-01-30 | 2005-08-18 | Eisai Co., Ltd. | Cholinesterase inhibitors for spinal cord disorders |
| EP1720847A1 (en) | 2004-02-02 | 2006-11-15 | Pfizer Products Incorporated | Histamine-3 receptor modulators |
| WO2005079807A1 (en) | 2004-02-13 | 2005-09-01 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists |
| CA2556214A1 (en) | 2004-02-13 | 2005-09-01 | Neuromolecular, Inc. | Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders |
| US20050182044A1 (en) | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
| CN102329267A (zh) | 2004-02-25 | 2012-01-25 | 伊莱利利公司 | 作为5-HT2C受体激动剂的6-取代的2,3,4,5-四氢-1H-苯并［d］氮杂䓬 |
| GB0405200D0 (en) | 2004-03-08 | 2004-04-21 | Pfizer Ltd | Combinations comprising alpha-2-delta ligands |
| US20060166998A1 (en) | 2004-03-12 | 2006-07-27 | Pfizer Inc | Pyrrolo[1,2-B]pyridazine compounds and their uses |
| US20060148807A1 (en) | 2004-03-12 | 2006-07-06 | Pfizer Inc | Pyrrolo[1,2b]pyridazine compounds and their uses |
| ATE533745T1 (de) | 2004-03-17 | 2011-12-15 | Pfizer Prod Inc | Neue benzyl(iden)-lactam-derivate |
| EP1740172A4 (en) | 2004-03-19 | 2007-10-10 | Axonyx Inc | ACETYLCHOLINESTERASE INHIBITORS AND N-METHYL-D-ASPARTATE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DISORDER |
| WO2005100334A1 (en) | 2004-04-14 | 2005-10-27 | Pfizer Products Inc. | Dipeptidyl peptidase-iv inhibitors |
| WO2005102272A2 (en) | 2004-04-21 | 2005-11-03 | Pfizer Products Inc. | Sustained-release dosage forms for cabergoline |
| WO2005108358A2 (en) | 2004-04-22 | 2005-11-17 | Eli Lilly And Company | Pyrrolidine derivatives useful as bace inhibitors |
| US20050245543A1 (en) | 2004-04-30 | 2005-11-03 | Pfizer Inc | Histamine-3 receptor antagonists |
| BRPI0510942A (pt) | 2004-05-11 | 2007-07-17 | Pfizer Prod Inc | combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b |
| MXPA06013520A (es) | 2004-05-21 | 2007-01-26 | Pfizer Prod Inc | Tetrahironaftilpiperazinas como antagonistas, agonistas inversos y agonistas parciales de 5-ht1b. |
| WO2005113535A2 (en) | 2004-05-21 | 2005-12-01 | Pfizer Products Inc. | Pyrazinylmethyl lactam derivatives |
| CA2569411A1 (en) * | 2004-06-04 | 2005-12-22 | Mood Management Sciences, Llc | Methods and compositions for treating mood disorder |
| US20070212428A1 (en) * | 2004-06-04 | 2007-09-13 | Mood Management Sciences, Inc. | Methods and compositions for treating mood disorder |
| WO2005121082A1 (en) | 2004-06-11 | 2005-12-22 | Ucb, S.A. | Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation |
| JP2008503560A (ja) | 2004-06-22 | 2008-02-07 | ファイザー・プロダクツ・インク | ジアザビシクロ系のヒスタミン−３受容体アンタゴニスト |
| BRPI0512406A (pt) | 2004-06-25 | 2008-03-04 | Pfizer Prod Inc | piridil piperazinas, composições farmacêuticas compreendendo as mesmas e intermediário para a sìntese das piridil piperazinas |
| US7572805B2 (en) | 2004-07-14 | 2009-08-11 | Bristol-Myers Squibb Company | Pyrrolo(oxo)isoquinolines as 5HT ligands |
| US7618980B2 (en) | 2004-07-14 | 2009-11-17 | Bristol-Myers Squibb Company | Pyrrolo(oxo)quinolines as 5HT ligands |
| US20060014733A1 (en) | 2004-07-19 | 2006-01-19 | Pfizer Inc | Histamine-3 agonists and antagonists |
| EP1771449A1 (en) | 2004-07-21 | 2007-04-11 | Pfizer Products Incorporated | Histamine-3 receptor antagonists |
| JP2008509212A (ja) | 2004-08-09 | 2008-03-27 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 中枢神経系障害の治療のための新規なキノキサリノンノルエピネフリン再吸収阻害剤 |
| MX2007002136A (es) | 2004-09-01 | 2007-04-02 | Pfizer Prod Inc | Antagonistas amino azabiciclicos del receptor 3 de la histamina. |
| BRPI0515143A (pt) | 2004-09-10 | 2008-07-08 | Pfizer Prod Inc | usos de derivados azabicìclicos de piridiloximetila e benzisoxazol para a preparação de uma composição farmacêutica para o tratamento dos distúrbios de humor |
| BRPI0514675A (pt) | 2004-09-10 | 2008-06-17 | Pfizer Prod Inc | ligantes de éter difenìlico terapêuticos |
| WO2006034196A1 (en) | 2004-09-17 | 2006-03-30 | Lifelike Biomatic Inc. | Compositions for enhancing memory and methods therefor |
| US20060069087A1 (en) | 2004-09-27 | 2006-03-30 | Pfizer Inc | Histamine-3 receptor antagonists |
| WO2006040688A2 (en) | 2004-10-12 | 2006-04-20 | Ernir Snorrason | Inhibitors of acetylcholinesterase for treating skin diseases |
| EP1802301A1 (en) | 2004-10-15 | 2007-07-04 | Pfizer Inc. | Treatment of bipolar disorders and associated symptoms |
| US7354951B2 (en) | 2004-10-18 | 2008-04-08 | Eli Lilly And Company | Substituted benzopyrans as selective estrogen receptor-beta agonists |
| CN101094846A (zh) | 2004-10-18 | 2007-12-26 | 伊莱利利公司 | 用作mglur3受体拮抗剂的1－(杂)芳基－3－氨基－吡咯烷衍生物 |
| WO2006060082A1 (en) | 2004-10-22 | 2006-06-08 | THE GOVERNMENT OF THE U.S.A. as represented by THE SEC., DEPT. OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH | Tricyclic compounds, preparation thereof and use thereof as cholinesterase activity inhibitors |
| WO2006046131A1 (en) | 2004-10-29 | 2006-05-04 | Pfizer Products Inc. | Tetralin histamine-3 receptor antagonists |
| WO2006048727A1 (en) | 2004-11-02 | 2006-05-11 | Pfizer Products Inc. | Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor |
| WO2006051407A1 (en) | 2004-11-15 | 2006-05-18 | Pfizer Products Inc. | Azabenzoxazoles for the treatment of cns disorders |
| WO2006051394A1 (en) | 2004-11-15 | 2006-05-18 | Pfizer Products Inc. | Azabenzoxazoles for the treatment of cns disorders |
| ATE460415T1 (de) | 2004-11-29 | 2010-03-15 | Warner Lambert Co | Therapeutische pyrazoloä3,4-büpyridine und - indazole |
| WO2006061711A1 (en) | 2004-12-07 | 2006-06-15 | Pfizer Products Inc. | 1, 2, 3, 3a, 8, 8a-hexahydro-2, 7a-diada-cyclopenta [a] inden-7-one derivatives which bind to neuronal nicotinic acetylcholine specific receptor sites and are useful in modulating cholinergic function and in the treatment of addictive disorders |
| EP1827468B1 (en) | 2004-12-23 | 2012-08-22 | Curaxis Pharmaceutical Corporation | Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease |
| EP1831172B1 (en) | 2004-12-28 | 2009-02-18 | Council of Scientific and Industrial Research | Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors |
| US20060183763A1 (en) | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
| PL1838716T3 (pl) | 2005-01-05 | 2011-09-30 | Lilly Co Eli | Dihydrat embonianu olanzapiny |
| EA014249B1 (ru) | 2005-01-27 | 2010-10-29 | Алембик Лимитед | Формуляция леветирацетама длительного высвобождения |
| WO2006086464A2 (en) | 2005-02-10 | 2006-08-17 | Bristol-Myers Squibb Company | Dihydroquinazolinones as 5ht modulators |
| FR2881618B1 (fr) | 2005-02-10 | 2007-04-13 | Centre Nat Rech Scient | Utilisation de composes derives de pyrimidinetrione en tant qu'inhibiteurs de l'acetylcholinesterase, compositions contenant ces derives et leurs utilisations en tant qu'insecticides |
| EP1853578A1 (en) | 2005-02-15 | 2007-11-14 | Eli Lilly And Company | Substituted tetralins as selective estrogen receptor-beta agonists |
| US20070298098A1 (en) | 2005-02-16 | 2007-12-27 | Elan Pharma International Limited | Controlled Release Compositions Comprising Levetiracetam |
| US8431156B2 (en) | 2005-02-22 | 2013-04-30 | Sun Pharma Advanced Research Company Ltd. | Pharmaceutical composition |
| WO2006090273A2 (en) | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia |
| WO2006090272A1 (en) | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia |
| JP2008534522A (ja) | 2005-03-30 | 2008-08-28 | ジェンファーム インク | 医薬組成物のための複合ステップ製造方法 |
| AU2006228426A1 (en) | 2005-04-01 | 2006-10-05 | Warner-Lambert Company Llc | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia |
| JP5666087B2 (ja) | 2005-04-06 | 2015-02-12 | アダマス・ファーマシューティカルズ・インコーポレーテッド | Ｃｎｓ関連疾患の治療のための方法及び組成物 |
| WO2006106416A1 (en) | 2005-04-08 | 2006-10-12 | Pfizer Products Inc. | PYRIDIL-LACTAMS AND THEIR USE 5 -HTl RECEPTORS LIGAN |
| ES2520015T3 (es) | 2005-04-08 | 2014-11-11 | Pfizer Products Inc. | [3.1.0]Heteroaril amidas bicíclicas como inhibidores de transporte de glicina de tipo 1 |
| US20080305161A1 (en) | 2005-04-13 | 2008-12-11 | Pfizer Inc | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions |
| US7741358B2 (en) | 2005-04-14 | 2010-06-22 | N.V. Organon | Crystal form of asenapine maleate |
| US20060241144A1 (en) | 2005-04-20 | 2006-10-26 | Albert Cha | Method for treating apathy syndrome |
| US7456188B1 (en) | 2005-04-28 | 2008-11-25 | Bristol-Myers Squibb Company | C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators |
| RU2007142346A (ru) * | 2005-05-31 | 2009-07-20 | Ориксиджен Серапьютикс, Инкорпорэйтд (Сша/Сша) (Us) | Способы и составы для контроля психотических нарушений |
| EP2308870A3 (en) | 2005-06-01 | 2011-10-19 | UCB Pharma S.A. | 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses |
| EP1731149A1 (en) | 2005-06-08 | 2006-12-13 | Ucb S.A. | Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy |
| JP2008543923A (ja) | 2005-06-22 | 2008-12-04 | ファイザー・プロダクツ・インク | ヒスタミン−３受容体アンタゴニスト |
| US20070015763A1 (en) | 2005-07-12 | 2007-01-18 | Pfizer Inc | Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist |
| CA2617102A1 (en) | 2005-07-28 | 2007-02-08 | Bristol-Myers Squibb Company | Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists |
| EP1924712B1 (en) | 2005-08-03 | 2018-10-03 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| WO2007017750A1 (en) | 2005-08-08 | 2007-02-15 | Pfizer Products Inc. | Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane |
| US7795436B2 (en) | 2005-08-24 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists |
| GB0517740D0 (en) | 2005-08-31 | 2005-10-12 | Novartis Ag | Organic compounds |
| WO2007026219A2 (en) | 2005-08-31 | 2007-03-08 | Pfizer Products Inc. | Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions |
| WO2007028082A1 (en) | 2005-09-01 | 2007-03-08 | Eli Lilly And Company | 6-substituted- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
| BRPI0615048A2 (pt) | 2005-09-01 | 2010-03-30 | Lilly Co Eli | composto, composição farmacêutica, e, uso de um composto |
| JP5249031B2 (ja) | 2005-09-01 | 2013-07-31 | イーライ リリー アンド カンパニー | ５−ＨＴ２Ｃ受容体アゴニストとしての６−Ｎ結合型へテロ環置換された２，３，４，５−テトラヒドロ−１Ｈ−ベンゾ［ｄ］アゼピン |
| WO2007028131A1 (en) | 2005-09-01 | 2007-03-08 | Eli Lilly And Company | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS |
| US20090215857A1 (en) | 2005-09-13 | 2009-08-27 | Pfizer Products Inc. | Therapeutic Pyrrolidines |
| US7745447B2 (en) | 2005-10-26 | 2010-06-29 | Bristol-Myers Squibb Company | Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists |
| US8618115B2 (en) | 2005-10-26 | 2013-12-31 | Bristol-Myers Squibb Company | Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| WO2007057742A2 (en) | 2005-11-18 | 2007-05-24 | Pfizer Products Inc. | Novel piperazinone derivatives |
| WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
| EP1963325A2 (en) | 2005-12-07 | 2008-09-03 | UCB Pharma, S.A. | Xanthine derivatives, processes for preparing them and their uses |
| WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
| NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| US20100222353A1 (en) | 2006-01-27 | 2010-09-02 | Pfizer Products Inc. | Aminophthalazine derivative compounds |
| WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| US7553836B2 (en) | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
| WO2007096743A1 (en) | 2006-02-23 | 2007-08-30 | Pfizer Products Inc. | Substituted quinazolines as pde10 inhibitors |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| EP1991212A1 (en) * | 2006-03-08 | 2008-11-19 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2007105053A2 (en) | 2006-03-13 | 2007-09-20 | Pfizer Products Inc. | Tetralines antagonists of the h-3 receptor |
| JP2009531323A (ja) | 2006-03-20 | 2009-09-03 | カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ | アセチルコリンエステラーゼ阻害剤として有用な薬剤組成物 |
| US20070224636A1 (en) | 2006-03-24 | 2007-09-27 | Pfizer Inc | Pyrrolo[1,2b]pyridazine compounds and their uses |
| CA2650711A1 (en) | 2006-04-28 | 2007-11-08 | Northwestern University | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
| JP2009535394A (ja) | 2006-05-02 | 2009-10-01 | ファイザー・プロダクツ・インク | Ｐｄｅ１０阻害剤としての二環式ヘテロアリール化合物 |
| US7858611B2 (en) | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| ES2444009T3 (es) | 2006-06-08 | 2014-02-21 | Ucb Pharma, S.A. | Co-cristales de pirrolidinonas |
| CA2654394A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
| US20080014271A1 (en) | 2006-07-13 | 2008-01-17 | Ucb, S.A. | Novel pharmaceutical compositions comprising levetiracetam |
| AU2007274710A1 (en) | 2006-07-14 | 2008-01-24 | Pfizer Products Inc. | Tartrate salt of (7S)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2R)-2-methylpiperazin-1-yl]-6,7-dihydro-5H-cyclopenta[b]pyridine |
| WO2008015516A1 (en) | 2006-07-28 | 2008-02-07 | Pfizer Products Inc. | Fused tricyclic heterocycles for the treatment of schizophrenia |
| US20080045512A1 (en) | 2006-08-09 | 2008-02-21 | Pfizer Inc. | Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane |
| WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| WO2008021666A2 (en) | 2006-08-18 | 2008-02-21 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
| WO2008020306A2 (en) | 2006-08-18 | 2008-02-21 | Pfizer Products Inc. | Isoindole derivatives |
| WO2008026046A1 (en) | 2006-08-30 | 2008-03-06 | Pfizer Products Inc. | Morpholine d3 dopamine antagonists |
| US20090298811A1 (en) | 2006-09-12 | 2009-12-03 | Pfizer Inc | Benzimidazolone derivatives |
| WO2008062446A2 (en) | 2006-09-14 | 2008-05-29 | Alembic Limited | An extended release composition of levetiracetam, which exhibits no adverse food effect |
| AU2007299726A1 (en) | 2006-09-22 | 2008-03-27 | Braincells, Inc. | Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis |
| PE20080926A1 (es) | 2006-10-23 | 2008-07-19 | Lilly Co Eli | Compuestos cb1 |
| AU2007309390A1 (en) | 2006-10-27 | 2008-05-02 | Medivation Neurology, Inc. | Methods and combination therapies for treating Alzheimer's disease |
| WO2008065500A2 (en) | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| CA2672212A1 (en) | 2006-12-11 | 2008-06-19 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors |
| WO2008074896A1 (en) | 2006-12-21 | 2008-06-26 | Prendergast Patrick T | Compositions and methods for treatment of chronic neurological disorders |
| WO2008084324A1 (en) | 2007-01-04 | 2008-07-17 | Pfizer Products Inc. | Naphthyridinone compound |
| EP2124933B1 (en) | 2007-01-22 | 2012-10-17 | Pfizer Products Inc. | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
| AU2008214380A1 (en) | 2007-02-02 | 2008-08-14 | Colucid Pharmaceuticals, Inc. | Compounds that inhibit cholinesterase |
| FR2912056B1 (fr) | 2007-02-05 | 2009-12-18 | Rd Pharmagal | Composition a liberation prolongee de levetiracetam et procede de preparation |
| WO2008095221A1 (en) | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of adhd |
| NZ578876A (en) | 2007-02-07 | 2012-12-21 | Pfizer | 3-amino-pyrrolo[3,4-c]pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors |
| EP2195321B1 (en) | 2007-04-12 | 2016-10-19 | Pfizer Inc. | 3-amido-pyrrolo[3,4-c]pyrazole-5(1h, 4h,6h) carbaldehyde derivatives as inhibitors of protein kinase c |
| JP2010525077A (ja) | 2007-04-25 | 2010-07-22 | ブリストル−マイヤーズ スクイブ カンパニー | 非塩基性メラニン凝集ホルモン受容体−１アンタゴニスト |
| WO2008132142A2 (en) | 2007-04-27 | 2008-11-06 | Ucb Pharma S.A. | New heterocyclic derivatives useful for the treatment of cns disorders |
| WO2008144305A1 (en) | 2007-05-18 | 2008-11-27 | Janssen Pharmaceutica N.V. | Diaryl-substituted tetrahydroisoquinolines as histamine h3 receptor and serotonin transporter modulators |
| US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| RU2339620C1 (ru) | 2007-07-09 | 2008-11-27 | Общество С Ограниченной Ответственностью "Фармвинг" | Оксалат n, n-диметил-2-n, n-диметиламинометилпиридил-3-карбамат, обладающий антихолинэстеразной активностью и способностью улучшать когнитивные функции |
| WO2009011412A2 (en) | 2007-07-13 | 2009-01-22 | Eisai R & D Management Co., Ltd. | Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain |
| US20090030403A1 (en) | 2007-07-27 | 2009-01-29 | Leyde Kent W | Methods and Systems for Attenuating the Tolerance Response to a Drug |
| KR20090031333A (ko) | 2007-09-21 | 2009-03-25 | 주식회사 엘지생명과학 | 신규한 베타-세크리타제 저해용 화합물 |
| US20090176740A1 (en) | 2007-11-30 | 2009-07-09 | Phillips Ii Dauglas James | Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine |
| CN101939306A (zh) | 2007-12-07 | 2011-01-05 | 美国辉瑞有限公司 | 反式-n-异丁基-3-氟-3-[3-氟-4-(吡咯烷-1-基-甲基)-苯基]环丁烷甲酰胺的甲苯磺酸盐 |
| US20100297181A1 (en) * | 2007-12-26 | 2010-11-25 | Eisai R&D Management Co., Ltd. | AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ |
| JP5345637B2 (ja) | 2008-01-22 | 2013-11-20 | イーライ リリー アンド カンパニー | κ選択的オピオイド受容体アンタゴニスト |
| WO2009098576A1 (en) | 2008-02-05 | 2009-08-13 | Pfizer Inc. | Pyridinyl amides for the treatment of cns and metabolic disorders |
| MX2010009222A (es) | 2008-03-03 | 2010-09-28 | Ucb Pharma Sa | Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos. |
| EP2276735A1 (en) | 2008-04-17 | 2011-01-26 | Pfizer Inc. | Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors |
| DK2280961T3 (da) | 2008-04-22 | 2012-08-27 | Lilly Co Eli | 1,5-diphenyl-pyrrolidin-2-on-forbindelser som cb-1-ligander |
| JP5539322B2 (ja) | 2008-04-22 | 2014-07-02 | イーライ リリー アンド カンパニー | Ｃｂ−１リガンドとしての１，５−ジフェニル−ピロリジン−２−オン化合物 |
| AR071997A1 (es) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
| US20110212944A1 (en) | 2008-07-01 | 2011-09-01 | Julie Liu | 2-oxo-1-pyrrolidine derivatives |
| JP2010024156A (ja) | 2008-07-16 | 2010-02-04 | Ucb Pharma Sa | レベチラセタムを含む医薬組成物 |
| TW201006801A (en) | 2008-07-18 | 2010-02-16 | Lilly Co Eli | Imidazole carboxamides |
| US7932256B2 (en) | 2008-07-31 | 2011-04-26 | Bristol-Myers Squibb Company | (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity |
| EP2331088A4 (en) | 2008-08-06 | 2011-10-12 | Gosforth Ct Holdings Pty Ltd | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES |
| DK3260118T3 (da) | 2008-10-16 | 2021-04-19 | Univ Johns Hopkins | Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion |
| US20100113465A1 (en) | 2008-10-30 | 2010-05-06 | Pfizer Inc. | 7-azaspiro[3.5]nonane-7-carboxamide compounds |
| US9125898B2 (en) | 2008-11-14 | 2015-09-08 | Neurotune Ag | Acetam derivatives for pain relief |
| US20100125094A1 (en) | 2008-11-17 | 2010-05-20 | Auspex Pharmaceuticals, Inc. | Pyrrolidinyl modulators of nicotinic acetylcholine receptors |
| AU2009317280B2 (en) | 2008-11-18 | 2014-03-06 | Ucb Pharma, S.A. | Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative |
| US20110230493A1 (en) | 2008-11-21 | 2011-09-22 | Pfizer Inc. | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors |
| US20100172979A1 (en) | 2008-12-24 | 2010-07-08 | Zhongshui Yu | Controlled-release formulations |
| CN104906085A (zh) | 2009-01-29 | 2015-09-16 | Ucb医药有限公司 | 含有2-氧代-1-吡咯烷衍生物的药物组合物 |
| EP2393483B1 (en) | 2009-02-09 | 2017-06-28 | UCB Biopharma SPRL | Pharmaceutical compositions comprising brivaracetam |
| EP2405913A1 (en) | 2009-03-09 | 2012-01-18 | Bristol-Myers Squibb Company | Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists |
| WO2010104818A1 (en) | 2009-03-09 | 2010-09-16 | Bristol-Myers Squibb Company | Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists |
| WO2010111080A2 (en) | 2009-03-27 | 2010-09-30 | Eli Lilly And Company | Optimized treatment of schizophrenia |
| US8846411B2 (en) | 2009-06-11 | 2014-09-30 | Microgenics Corporation | Derivatives, reagents, and immunoassay for detecting levetiracetam |
| WO2010146488A1 (en) | 2009-06-18 | 2010-12-23 | Pfizer Inc. | Bicyclic and tricyclic compounds as kat ii inhibitors |
| WO2011015349A2 (en) | 2009-08-07 | 2011-02-10 | Ucb Pharma, S.A. | Methods for enhancing the cognitive function |
| CN101647789B (zh) | 2009-09-01 | 2011-08-17 | 天津药物研究院药业有限责任公司 | 左乙拉西坦缓释微丸胶囊制剂 |
| WO2011049309A2 (ko) | 2009-10-09 | 2011-04-28 | 영진약품공업 주식회사 | 속효성과 지속성을 동시에 갖는 약제학적 조성물 |
| WO2011057199A1 (en) * | 2009-11-06 | 2011-05-12 | Adenios, Inc. | Compositions for treating cns disorders |
| ES2436241T3 (es) | 2009-11-16 | 2013-12-27 | Eli Lilly And Company | Compuestos de espiropiperidina como antagonistas de receptor oral-1 |
| UA107943C2 (xx) | 2009-11-16 | 2015-03-10 | Lilly Co Eli | Сполуки спіропіперидину як антагоністи рецептора orl-1 |
| AR079343A1 (es) | 2009-12-21 | 2012-01-18 | Lilly Co Eli | Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico |
| EA202092673A3 (ru) | 2010-02-09 | 2021-05-31 | Дзе Джонс Хопкинс Юниверсити | Способы и композиции для улучшения когнитивной функции |
| WO2011143721A1 (en) | 2010-05-21 | 2011-11-24 | Gosforth Centre (Holdings) Pty Ltd | Compositions and methods for treating neurodegenerative disorders |
| CA2804165C (en) | 2010-07-08 | 2015-02-24 | Pfizer Inc. | Piperidinyl pyrimidine amides as kv7 potassium channel openers |
| US20130184294A1 (en) | 2010-09-21 | 2013-07-18 | Pfizer Inc. | Pyrimidones for Treatment of Potassium Channel Related Diseases |
| RU2541159C2 (ru) | 2010-10-26 | 2015-02-10 | АЛФАРМА ФАРМАСЬЮТИКЭЛЗ, ЭлЭлСи | Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов |
| KR20120055313A (ko) | 2010-11-23 | 2012-05-31 | 주식회사 바이오파마티스 | 레베티라세탐 또는 이의 약학적으로 허용되는 염을 포함하는 용출 안정성이 개선된 서방형 약학 조성물 및 이의 제조방법 |
| DK2646443T3 (en) | 2010-12-01 | 2014-11-17 | Pfizer | CAT-II inhibitors |
| EP2646417A1 (en) | 2010-12-01 | 2013-10-09 | Pfizer Inc | Kat ii inhibitors |
| BR112013020283A2 (pt) | 2011-02-09 | 2016-07-19 | Univ Johns Hopkins | "uso de inibidor de proteína de vesícula sináptica 2a (sv2a), valproato, levetiracetam, brivarecetam e seletracetam no tratamento de deficiência cognitiva, bem como composição farmacêutica compreendendo os mesmos" |
| KR101548443B1 (ko) | 2011-02-23 | 2015-08-28 | 화이자 인코포레이티드 | 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진 |
| DE102011103270A1 (de) | 2011-05-26 | 2012-11-29 | Stada Arzneimittel Ag | Pulverförmige Mischung zur Herstellung von Levetiracetam-haltigen Tabletten |
| GB201111712D0 (en) | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| US20160030391A1 (en) | 2013-03-15 | 2016-02-04 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| AU2014228512A1 (en) | 2013-03-15 | 2015-10-01 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| CA2986598C (en) | 2015-05-22 | 2023-09-26 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
-
2013
- 2013-11-14 US US14/080,531 patent/US20140206667A1/en not_active Abandoned
- 2013-11-14 EP EP13854262.6A patent/EP2919788A4/en not_active Withdrawn
- 2013-11-14 HK HK16103149.6A patent/HK1215170A1/zh unknown
- 2013-11-14 JP JP2015542047A patent/JP6440625B2/ja active Active
- 2013-11-14 WO PCT/US2013/070144 patent/WO2014078568A1/en not_active Ceased
- 2013-11-14 US US14/442,996 patent/US10154988B2/en active Active
- 2013-11-14 EP EP19184005.7A patent/EP3610890A1/en active Pending
- 2013-11-14 CA CA2891122A patent/CA2891122C/en active Active
-
2017
- 2017-06-21 US US15/629,314 patent/US10624875B2/en active Active
-
2018
- 2018-02-14 JP JP2018024298A patent/JP2018090609A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2919788A1 (en) | 2015-09-23 |
| US20180125818A1 (en) | 2018-05-10 |
| EP3610890A1 (en) | 2020-02-19 |
| CA2891122A1 (en) | 2014-05-22 |
| US20150313876A1 (en) | 2015-11-05 |
| CA2891122C (en) | 2021-07-20 |
| US20140206667A1 (en) | 2014-07-24 |
| WO2014078568A1 (en) | 2014-05-22 |
| EP2919788A4 (en) | 2016-05-25 |
| US10624875B2 (en) | 2020-04-21 |
| JP2018090609A (ja) | 2018-06-14 |
| JP2015537003A (ja) | 2015-12-24 |
| US10154988B2 (en) | 2018-12-18 |
| HK1215170A1 (zh) | 2016-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6440625B2 (ja) | 精神分裂病を処置するための方法および組成物 | |
| US20230277501A1 (en) | Methods and compositions for improving cognitive function | |
| AU2021200325B2 (en) | Methods and compositions for improving cognitive function | |
| JP6433482B2 (ja) | 認知機能を改善するための方法および組成物 | |
| US20160030391A1 (en) | Methods and compositions for improving cognitive function | |
| AU2018208662B2 (en) | Methods and Compositions for Treating Schizophrenia | |
| HK40021943A (en) | Methods and compositions for treating schizophrenia | |
| HK40003608A (en) | Methods and compositions for improving cognitive function | |
| RU2792010C2 (ru) | Способы и композиции для улучшения когнитивных функций | |
| AU2013344646A1 (en) | Methods and compositions for treating schizophrenia | |
| HK1192821A (en) | Methods and compositions for improving cognitive function | |
| HK1261244A1 (en) | Levetiracetam for improving cognitive function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161114 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161114 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170814 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171030 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180214 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180510 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180910 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20180919 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181018 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181102 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181115 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181120 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6440625 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |